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Abstract 
Iron is the most common and perhaps the most crucial transition metal.  It is essential for 
virtually all of life yet it is also potentially extremely toxic; therefore, how organisms handle iron 
(iron metabolism) is of critical importance. Ferritins constitute a large family of iron storage 
proteins that are found throughout life, in bacteria, archaea, plants and animals. The newly 
discovered ferritin from the bloom-forming pennate diatom Pseudo-nitzschia multiseries is 
similar to other eukaryotic ferritins that contains a ferroxidase centre but also contains a third site 
(site C) only previously found in non-heme bacterial ferritins.  The mechanism of iron uptake in 
P. multiseries ferritin and the effect of substitution of residues at site C has been studied using 
rapid reaction kinetic methods.  These revealed that oxidation in PmFTN is very rapid suggesting  
a distinct mechanism of iron uptake. 
 Bacterioferritin (BFR) is a unique heme-containing bacterial member of the ferritin family that 
stores up to 2700 iron ions as a ferric oxyhydroxide phosphate mineral within its central cavity. 
This core is surrounded by 24 identical protein subunits, each of which possesses a dinuclear iron 
centre that catalyses the oxidation of Fe(II) to Fe(III). The heme-binding sites are sandwiched 
between pairs of subunits and coordinated by two methionine residues (one from each subunit). 
The heme groups play an important role in iron release, though understanding of this has been 
hampered by the difficulty in obtaining fully heme-loaded protein that is isolated from over-
expressing bacterial cultures.  Here, an in vitro heme-loading method is described and used to 
generate BFR containing variable amounts of heme.  Studies of iron release indicate increased 
heme levels only marginally increases the rate of iron release and actually lowers the extent of 
iron release.  These results suggest that the reconstituted heme-loaded protein behaves differently 
from naturally heme-loaded protein. 
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Abbreviations 
% v/v  volume of substance in mL per 100 mL of total solution  
% w/v weight of substance in grams per 100 mL of total solution 
ε Extinction coefficient (M-1 cm-1) 
ΔA change in absorbance  
µl microlitre (1 µl = 10-6 L) 
µM micromolar (1 µM = 10-6 M) 
A Absorbance 
BCA Bicinchoninic acid 
BFR Bacterioferritin 
BSA Bovine serum albumin 
DPS DNA binding protein from starved cells 
EDTA Ethylenediaminetetraacetic acid 
Ftn ferritin  
FtnA non-heme bacterial ferritin 
Hepes  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
IPTG Isopropyl β-D-thiogalactopyranoside  
L litre 
M molar, unit of concentration (moles per liter) 
MES 2-(N-morpholino)ethanesulfonic acid 
mL millilitre (1 mL = 10-3 L) 
mM millimolar (1 mM = 10-3 M) 
MOPS 3-(N-morpholino)propanesulfonic acid 
NHE normal hydrogen electrode 
PAGE polyacrylamide gel electrophoresis 
PDB protein data bank 
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PmFTN Pseudo-nitzschia multiseries ferritin 
rpm revolutions per minute 
SDS sodium dodecyl sulfate 
TEMED N,N,N',N'-tetramethylethylenediamine 
Tris tris(hydroxymethyl)aminomethane 
U.V. ultraviolet  
Wt wild type 
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Chapter 1:  Introduction 
 
1.1     The chemistry and biology of iron 
With a few exceptions, virtually all studied organisms need iron for survival. Most organisms 
utilize iron as a cofactor for fundamental biochemical activities, such as oxygen transport, 
nitrogen fixation, electron transfer reactions, photosynthesis, respiration, and DNA synthesis (1). 
Iron can be incorporated into proteins as iron-sulfur clusters, mononuclear iron sites, dinuclear 
iron sites, mixed metal dinuclear sites, and heme. This is due to the flexible coordination 
chemistry and redox reactivity of iron, which allow it to associate with proteins and bind to 
oxygen, transfer electrons or mediate catalytic reactions. In the Earth’s crust, iron is the second 
most abundant metal and fourth most abundant element. However, iron is also poorly available 
and potentially toxic due to atmospheric dioxygen.  The thermodynamically stable ferrous (Fe2+)  
(E° Fe 3+ / Fe2+ = +0.77 volts versus NHE) is converted to ferric (Fe3+) form, in the presence of 
dioxgyen (E° O2 / H2O = +1.23 volts versus NHE).  This is significant because in aqueous 
solution at neutral pH values ferrous iron is soluble (up to 0.1 M), whereas the ferric form is 
insoluble (up to1.4 x 10-9 M, depending on pH) therefore limiting the concentration of iron (2, 3). 
Therefore, the oxidised Fe3+ is poorly bioavailable, despite its high abundance, due to limited 
solubility. Furthermore, in the presence of reductant(s) and dioxygen, iron can cycle between the 
ferrous and ferric forms, leading to reduction of O2 to superoxide (•O-2), hydrogen peroxide 
(H2O2) and the hydroxyl radical (OH•) (4).  This chemistry is summarised in the following 
equations (Eq. 1-3) : 
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                                                            Fe(III) + •O-2   → Fe(II) + O2                                             (Eq.1) 
  Fenton Reaction                             Fe(II) + H2O2  → •OH + OH− + Fe(III)                    (Eq.2) 
                    ______________________________ 
  Haber-Weiss Reaction       Overall è          •O-2  + H2O2   → •OH + OH− + O2                                           (Eq.3) 
 
Hydroxyl radicals, in particular, will react essentially instantaneously with all types of biological 
macromolecules like DNA, proteins and membrane lipids, typically disturbing their activity and 
sometimes damaging them completely (5).  As iron readily shuttles between the reduced ferrous 
and the oxidised ferric forms, disruption of the cellular redox equilibrium requires only catalytic 
amounts of the metal. Despite its clear importance, organisms are challenged with the 
paradoxical hazard of iron deficiency and iron overload, each with its serious or fatal 
consequences. To prevent iron toxicity and iron-induced oxidative stress associated with damage 
of cellular macromolecules, tissue injury and disease, organisms have developed sophisticated 
mechanisms to control iron in the cell. These mechanisms involve iron-storage proteins 
belonging to the ferritin family, which store low solubility and low availability iron and make it 
available as needed for anabolic processes. Ferritins have been intensively studied for several 
decades and much is known about their ability to store iron in a soluble, bioavailable, non-toxic 
form, that is readily accessible when needed (1, 3).  
1.2     Overview of ferritin and ferritin-like proteins  
Ferritin is ubiquitously found in most, plants, animals, microorganisms with the exception of 
yeast. Ferritins were first discovered in higher eukaryotes, with a unique molecular architecture, 
comprising 24 structurally similar subunits of H (heavy) and L (light) type. Each of these 
subunits is composed of a four helical bundle with a fifth short helix at the C-terminal. 
Mammalian ferritins are all heteropolymers of 24 subunits that form a roughly spherical shell (of 
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~ 120 Å diameter) with a 4,3,2 octahedral symmetric arrangement (as shown in Figure 1.1) that 
encloses the central iron storage cavity (of ~70 Å diameter). The two types of subunit, (H) heavy 
chain and (L) light chain, with an apparent molecular weight of 21 kDa or 19 kDa, respectively, 
are closely related in sequence and structurally homologous.  In ferritin, the assembled 24 
subunits are held tightly together leaving eight narrow (about 4 Å wide in diameter) hydrophilic 
channels at the 3-fold axes and six hydrophobic channels at the 4-fold axes (6-8).  
Ferritins were subsequently discovered in plants, bacteria and archaea, in which all of the 
subunits are H-chain-like. In bacteria, there are different types of ferritins; often several of these 
are present in a single cell. Several ferritin or ferritin-like proteins are found in Escherichia coli 
(E. coli) such as bacterial ferritin (FtnA and FtnB, the latter of which does not contain a 
recognisable catalytic centre, bacterioferritin and Dps (DNA binding protein from starved cells). 
No evidence has yet been presented for the co-assembly of subunits making up these different 
proteins, but this remains a possibility. E. coli FtnA is composed of a subunit (~19.5 kDa) that in 
terms of sequence is approximately 22% identical to eukaryotic H-chain ferritin, but in terms of 
structure bears a remarkable similarity. The 3-fold channels are lined by both hydrophobic and 
hydrophilic residues and are significantly less polar than their eukaryotic ferritin counterparts. 
The 4-fold channels are polar at both ends and hydrophobic in character in their central part.  
Distinct channels, called B-channel, are present in prokaryotic ferritins only. These are 
hydrophilic in nature and occur where one subunit dimer meets another in a side-on fashion, such 
that there are 12 such channels per ferritin (9).  It is possible that B-channels in BFRs and Ftns 
are functionally comparable to eukaryotic ferritin three-fold channels (9, 10).  
It has been suggested that the core mineralisation of Ftn occurs via a mechanism similar to that 
of eukaryotic H-chain ferritin but is more complicated due to the presence of site C, a third iron 
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binding site that exists in FtnA, and which is believed to cause some of the mechanistic 
differences observed between these two proteins (11).  FtnB lacks several of the crucial residues 
that form the catalytic centre of the FtnA subunit.  Although less well characterized than FtnA, 
FtnB is not believed to be capable of forming heteropolymers with FtnA because of the lack of 
residues important for inter-subunit interactions in FtnA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Structure of prokaryotic ferritin. Cartoon representations of ferritin looking down 
four-fold (A) and three-fold (B) axes (12).  The subunit dimer are represented in various colour 
and the sphere represent iron at the ferroxidase centre. Figure generated from PDB 3GHQ. This 
and other structural figures were prepared using Pymol (12). 
 
Dps is the most recently recognized member of the ferritin family. It has a spherical shell-like 
structure of 3:2 tetrahedral symmetry and is composed of just 12 identical α-helical ferritin-like 
subunits, rather than the 24 subunits observed in other ferritins (13).  
  
 
 
	  
	  
A	   B	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1.3   Physiological role of iron storage proteins  
Ferritins have been shown to play different roles in different species of bacteria.  Therefore, the 
exact physiological roles of any one type of proteins are challenging to define. This is, in part, 
due to the presence of various types of iron storage protein in the same bacterial cell. Studies in 
E. coli and Porphyromonas gingivalis have shown that FtnA is important for iron storage (14, 
15) and in most cases is probably the principal iron storage protein of cells. Cells have developed 
different mechanisms to counter the problem that iron imposes as a facilitator of oxygen radical 
chemistry. While Dps protein is capable of binding and storing up to 500 ferric ions and is 
structurally related to ferritins, its sole function appears to be to protect the genome from iron-
induced free radical damage (16). It does this by two mechanisms. First, Dps binds DNA to 
protect it physically from oxidative attack.  Secondly, free iron is bound and oxidised by 
hydrogen peroxide in preference to dioxygen, thus removing the reactants for the Fenton reaction 
(17). Although Dps possesses dinuclear iron sites, these sites are not located in the centre of each 
subunit, as they are in other ferritins (see section 1.4), but are constructed between pairs of 
adjacent subunits with each subunit contributing residues that provide ligands for binding iron.  
BFRs are believed to be mainly involved in iron storage and protection against oxidative stress.  
In Neiserria gonorrhoeae and Salmonella enterica serovar Typhimurium BFR has been shown to 
play important roles in iron storage and protection against oxidative stress under iron-rich 
conditions, while in Brucella melitensis BFR apparently does not have a role in protecting the 
cells against oxidative stress (17, 18). BFR from Pseudomonas aeruginosa provides iron for the 
heme prosthetic group of KatA, a catalase that is important for protecting the cell against 
hydrogen peroxide stress (17, 19). Interestingly, E. coli BFR minimizes the formation of 
hydroxyl radicals from the oxidation of ferrous ions by hydrogen peroxide in vitro. BFR avoids 
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Fenton chemistry thus preventing the production of reactive oxygen species and oxidative 
damage to DNA and other cell components. It does this by catalyzing the two-electron reduction 
of hydrogen peroxide to water (20).  
 
1.4 Mechanism of iron uptake in Eukaryotic ferritin 
Studies suggest that in eukaryotic ferritins, the eight hydrophilic channels function in iron uptake 
and exit, while the four-fold hydrophobic channels are possibly involved in diffusion of O2 and 
H2O2 (8, 20, 21). The H-chain subunit of eukaryotic ferritin contains a dinuclear iron centre, 
known as the ferroxidase centre, located at the centre of the four alpha-helical bundle.  The 
centre is essential for rapid oxidation of Fe(II) to Fe(III) and much work has focused on 
establishing the mechanistic role of the centre in the mineralisation reaction (8, 22). The 
ferroxidase centre consists of site A and B as shown in Figure 1.2A.   
 
                                  
 
Figure 1.2. Schematic representations of (A) the ferroxidase centre of human H-chain 
ferritin, (B) the symmetric ferroxidase centre of E. coli BFR and (C) the ferroxidase 
centre of FtnA in E. coli . Iron in the dinuclear centre is in the ferric form. 
 
A detailed look at the ferroxidation reactions reveals that ferritins of various organisms are 
characterized by a diverse chemistry of iron deposition and release. In eukaryotic ferritins, in 
B	  A	   C	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order to reach the active sites, the Fe(II) substrate crosses the protein cage from the cytoplasmic 
surface of the cage to the multiple active sites.  This is believed to occur via the three fold 
channels and involves a conserved Glu residue (in each of the three subunits) that forms a 
constriction half way down the channel (23, 24).  
After Fe(II) passes through the channels, it binds to the ferroxidase centre in pairs and promptly 
reacts with dioxygen to form an intermediate, a µ-1,2-peroxodiferric intermediate that gives a 
characteristic blue colour ( λ max at 650 nm). This decays in seconds as indicated the in equation 
5, to a more stable µ-1,2-oxodiferric species (see Equations 4 and 5). The oxidation of two Fe(II) 
ions is a two electron process and so the expected O2 reduction product is H2O2 (25) . The µ-
oxodiferric species generated by the ferroxidase reaction is itself unstable and this has hindered 
attempts to structurally characterize the oxidised form of the FC (ferroxidase centre). The 
stoichiometric release of H2O2 is generally not detected, indicating that further reactions take 
place, although these cannot be Fe(II) oxidation reaction because, if they were, the ratio of 
2Fe:1O2 would not be observed (9).  
[FeII   FeII]FC     +    O2   →  [FeIII ... -O—O- ... FeIII]                                        (Eq.4) 
[FeIII ... -O—O- ... FeIII]  +     H2O   → [FeIII ... O2- ... FeIII]    +  H2O2      (Eq.5) 
Recently, it was shown by NMR spectroscopy that the pathway of Fe(III) following its exit from 
the FC involves a ‘channel’ running along the long subunit axis, entering the cavity at the four 
fold channel, that is where four such intra-subunit Fe(III) pathways converge (26). Once in the 
central cavity, Fe(III) which may transit as Fe(III)2O units, either attaches to the existing 
minerals or bind at nucleation sites initiating mineralization (25). L-chain subunits are 
isostructural with H-chain subunits but lack residues that form the FC catalytic centre.  However, 
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they contain an acidic patch on their cavity-facing surface which is important for efficient 
nucleation of the core mineral (8, 22). 
The precise nature of Fe(III) species at defined time points during the mineralisation process is 
difficult to establish unequivocally.  The process may be viewed simply as the hydrolysis of 
[Fe(III)2O] units that result from oxidation of Fe(II) at the ferroxidase centre.  This species could 
be already partially hydrated before it attaches to the existing mineral/nucleation sites:  
[FeIII ... O2- ... FeIII]+  2H2O   →  [FeIII ... -OH... O2- ... -OH ...FeIII]  +   2H+   (Eq.6) 
and subsequently undergoes further hydration/hydrolysis:  
[FeIII ... -OH... O2- ... -OH ...FeIII]  +  H2O   →  2[FeIII … (O2-)(-OH)]  +  2H+               (Eq.7) 
The product here is ferric oxyhydroxide and this is believed to resemble in structure the mineral 
ferrihydrite (5Fe2O3 . 9H2O).  There is a lack of detailed structural information about ferritin 
mineral cores because in crystals of iron core-containing ferritins, although the protein cages are 
well ordered, the minerals inside them need not be, and the electron density due to iron mineral 
is not observed. When larger amounts of iron are added to eukaryotic ferritins, the mineral 
surface can serve as an alternative catalytic site for Fe(II) oxidation and O2 reduction:  
4[Fe(II)]cavity  +  O2  +  6H2O → 4[FeIII … (O2-)(-OH)]cavity  +  8H+  (Eq.8) 
These observations initially led to the crystal growth model of mineralisation (9).  
1.5 Mechanism of iron release from Eukaryotic ferritin 
The ferritin mineralisation reaction can be reversed through the addition of electrons and protons 
(and water), leading to dissolution of the mineral. This reaction can be followed in vitro using a 
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range of reductants, some of which are likely to be physiologically relevant (such as 
NADH/FMN) (27), together with a chelator that is not physiological but which forms a coloured 
species, enabling the whole process to be followed kinetically (28). 
Although measuring iron release (or at least formation of Fe(II)-chelates) is straightforward, the 
reaction itself is complex and it is not known whether the reductant contacts the mineral surface 
directly, or supplies electrons remotely via a transfer chain.   
In frog ferritin, it has been shown that the three-fold channels play a key role in the exit of iron 
from the cavity. Studies revealed that increasing temperature and physiological concentrations of 
urea leads to opening of the channels, due to localized unfolding. The amino acids residues 
responsible for the formation of the gated pore are: (Arg 72–Asp 122) that form an ion pair, 
(Leu134–Leu110) that form a hydrophobic interaction, and (N-terminus-Arg 72) by hydrogen 
bond interactions. A mutation of any of these residues remarkably increases the ability of iron to 
migrate out of the interior of the ferritin cage during reductive iron release studies (21, 29).   
Another mechanism of iron release from eukaryotic ferritins involves lysosomal degradation of 
the ferritin protein shell.  Lysosomes are membrane-bound compartments that contain many 
proteolytic enzymes and proton pumps that decrease the local pH.  Although ferritin does 
accumulate in lysosomes under conditions of iron over-supply, this route of iron release is not 
likely to be a major one under normal circumstances.  From what is now known about the 
complexities of iron metabolism, it also would make little sense for the cell to release large 
amounts of iron at one time, as this would lead to iron toxicity (29).  
1.6     Pseudo-nitchia multiseries Ferritin  
About 30-40% of the world’s oceans contain low iron concentrations that limit the growth of 
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phytoplankton. Moreover, it was recently discovered that marine algae blooms, which result 
from periodic iron deposition from atmospheric dust and flow from the deep ocean, are 
dominated by pennate diatoms (Pseudo-nitzshia and Fragilariopsis) that contain ferritin (30). 
Until recently ferritin has not been identified in any member of the Stramenopiles, a diverse 
eukaryotic lineage that includes macroalgae, unicellular algae and plant parasites.  Through 
phylogenetic analyses it has been suggested that lateral gene transfer accounts for the occurrence 
of ferritin in this small subset of diatoms. Storing iron in ferritin is one mechanism that confers a 
growth advantage, enabling them to better survive the low iron conditions that normally prevail 
in the oceans. The structure of pennate diatom ferritin from Pseudo-nitzshia multiseries 
(PmFTN) has been reported and is made up of an assembly of 24 monomers (Figure 1.3) 
forming a hollow sphere with a diameter of approximately 120 Å, typical of the ferritin family 
(30).  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3.  Crystal structure of Pseudo-nitzschia multiseries ferritin, a 24meric protein.  
The protein is viewed down one of six four-fold axes.  The figure was generated from 
PDB 3E6R using Pymol (12). 
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Analysis of mineralisation activity revealed that the protein exhibits ferroxidase activity and was 
able to support the oxidation of at least 600 Fe(II) per protein, with a Fe:O2 ratio of ~ 2:1.  This 
indicates that H2O2 is the product of O2 reduction, a conclusion supported by the regeneration of 
O2 upon addition of catalase (30).  In order to mimic sporadic blooms as seen in nature, iron 
limited PmFTN cells were re-supplied with a pulse of iron and immediate growth rate and 
ferritin transcription increase was seen. When the iron level was depleted it gradually returned to 
an iron sufficient state. This shows PmFTN ferritin provides protection from oxidative stress by 
immediately responding to excess iron, as well as iron storage for longer survival (30).    
1.7 Structural features of PmFTN  
 
1.7.1 Ferroxidase centre and site C 
Ferritin from the diatom Pseudo-nitzschia multiseries is structurally similar to other eukaryotic 
ferritins.  The folded monomers contain 168 amino acids and is similar to eukaryotic, bacterial 
and archeal ferritin and less related to BFR and Dps ferritins. It also contains three free cysteines 
that are not usually found in other characterized ferritins. The folded monomer includes four 
long alpha-helices as well as a short fifth alpha-helix at the C-terminus. The hollow 
dodecahedron is composed of 24 monomers with a similar highly symmetric arrangement as 
observed in all other eukaryotic ferritins.  The protein is approximately 120 Å across with a 
molecular mass of ~530 kDa. The residues that form the ferroxidase site in other eukaryotic 
ferritins are conserved consistent with the catalytic activity observed (31).  
The crystal structure of P.multiseries ferritin containing iron revealed iron sites at and near the 
ferroxidase centre. Site A of the ferroxidase centre did not contain iron but instead contained a 
water molecule. Site B was fully occupied with iron coordinated by Glu44, Glu48, Glu120 and 
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Glu 130. Iron was also located at an additional site, termed site C, with 50% occupancy 
coordinated by one glutamate residue (Glu44).   This was a surprising finding because iron 
binding sites close to the ferroxidase centre have not been observed previously in eukaryotic 
ferritins.  They have been observed in bacterial ferritins in which they are also referred to as site 
C (30).  The site C observed in PmFTN is related to (but distinct from) that of bacterial ferritins, 
see alignment in Figure 1.4. 
Figure 1. 4. Amino acid sequence alignment of Pseudo-nitzschia multiseries FTN 
(PmFTN), FtmA, BFR, E. coli and Human L and H chains. Alignment was performed 
using ClustalW (77) and the ﬁgure generated using Genedoc (78). Residue numbers are 
indicated on the right. Asterisks indicate residues that serve as ligands at the ferroxidase 
centre of PmFTN and BFR.  Black arrow indicates residues that coordinate iron at site C 
in PmFTN. 
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PmFTN   : 
FtnA    : 
BFR     : 
L-chain : 
H-chain : 
          
                                                  
                                                  
GMAAYMLAESAEEREHGLGFVDFANKRNIPIELQAVPAPVSCAEWSSPED
GAAAFLRRHAQEEMTHMQRLFDYLTDTGNLPRINTVESPF--AEYSSLDE
RLNDVEYHESIDEMKHADRYIERILFLEGLPNLQDLGKLN---IGEDVEE
GVSHFFRELAEEKREGYERLLKMQNQRGGRALFQDIKKPA-EDEWGKTPD
NFAKYFLHQSHEEREHAEKLMKLQNQRGGRIFLQDIQKPD-CDDWESGLN
                                                  
      
      
 :  86
 :  85
 :  85
 :  94
 :  99
      
          
          
PmFTN   : 
FtnA    : 
BFR     : 
L-chain : 
H-chain : 
          
                                                  
                                                  
VWQSILELEQANTRSLLNLAEAASTCHDFAVMAFLNPF-HLQQVNEEDKI
LFQETYKHEQLITQKINELAHAAMTNQDYPTFNFLQWY-VSEQHEEEKLF
MLRSDLALELDGAKNLREAIGYADSVHDYVSRDMMIEI-LRDEEGH---I
AMKAAMALEKKLNQALLDLHALGSARTDPHLCDFLETHFLDEEVKL---I
AMECALHLEKNVNQSLLELHKLATDKNDPHLCDFIETHYLNEQVKA---I
                                                  
      
      
 : 135
 : 134
 : 131
 : 141
 : 146
      
          
          
PmFTN   : 
FtnA    : 
BFR     : 
L-chain : 
H-chain : 
          
                                     
                                     
GSILAKVTDENRTPGLLRSLDVVSFLGPCLFRS----
KSIIDKLSLAGKSG---EGLYFIDKELSTLDTQN---
DWLETELDLIQKMG-------LQNYLQAQIREEG---
KKMGDHLTNLHRLGGPEAGLGEYLFERLTLKHD----
KELGDHVTNLRKMGAPESGLAEYLFDKHTLGDSDNES
                                     
      
      
 : 168
 : 165
 : 158
 : 174
 : 183
      
*	   ^	  
*	  
*	  *	  
*	  
*	   ^	   *	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A second iron site outside the ferroxidase centre was also observed with lower occupancy than 
site C which may represent a route for iron from the ferroxidase centre to the cavity (32). The 
mechanism of iron mineralisation is not understood see Figure 1.5.  
 
 
 
 
 
 
Figure 1.5. Ferroxidase site of Pseudo-nitzschia multiseries ferritin. (A) Monomer of α 
helices and ferroxidase centre side chains (shown in teal) and iron atoms (shown in red). 
(B) Ferroxidase centre: site A is occupied by a water molecule (water molecule is not 
shown here). Iron (shown in red) occupies site B at full occupancy, and is coordinated 
by four glutamates (Glu44, Glu48, Glu94, and Glu130).  
 
1.7.2 Comparison of PmFTN with bacterial ferritin 
Bacterial ferritin appears only distantly related to eukaryotic H-chain ferritins in terms of 
sequence identity (approximately 22%), yet it shares unusual structural similarity to human H-
chain.  It has the same subunit structure and 24meric arrangement and possesses six 4-fold 
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channels and eight 3-fold channels.  The 4-fold channels are hydrophobic in character in their 
middle part and polar at both ends.  The 3-fold channels are covered by both hydrophobic and 
hydrophilic residues, but are considerably less polar than their eukaryotic counterparts (8).  
Bacterial ferritins contain another type of channel first identified in BFR and not present in 
eukaryotic ferritins (9). These are located where one subunit dimers contacts another (essentially 
the edges of each of the dodecahedron’s 12 faces, hence there are 12 such channels per protein). 
It is suggested that B-channels might be functionally equivalent to 3-fold channels in eukaryotic 
ferritins because they are polar in nature.  Evidence in support of this is thus far lacking.  
 
 
 
 
 
 
 
 
 
Figure 1.6. The ferroxidase centre and Site C of E. coli of FtnA.  (A) Stick 
representation of the bridged di-Fe(III) form of the E. coli FtnA ferroxidase centre. (B) 
A rotated view from under the ferroxidase centre showing Fe(III) at the closely lying 
site C (shown in purple Gln127) (PDB 1EUM). 
 
FtnA, a bacterial ferritin from E. coli, has a dinuclear ferroxidase site, where Fe(III) is bound at 
site A (see Figure 1.6) where it is ligated by monodentate glutamate (Glu17) and histidine (His53) 
residues and a bridging glutamate (Glu50). At site B, Fe(III) is ligated by Glu50 and two 
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monodentate glutamates (Glu94 and Glu130).  Furthermore, a water molecule was coordinated to 
Fe(III) at site A and a second water bridges the irons, although this is more likely to be  an oxo- 
or hydroxo-bridge (33). Site B occupancy was found to be slightly lower compared to site A.  
Furthermore, site B coordination resembles that of H-chain ferritin, with one difference: residue 
Glu61 in human H-chain ferritin is replaced as a metal ligand by Glu130 (8, 9). There is some 
debate about whether Glu61 is actually a ligand to the iron at site B. In addition, FtnA also has a 
third iron-binding site, site C, located towards the subunit surface. The iron at this site (Figure 
1.6) is coordinated by Glu129, Glu49, Glu130 and Glu126 (8, 9). Mutagenesis of site C residues 
suggested that site C is not essential for ferroxidase activity, because this resulted in only a slight 
reduction in oxidation rate. Therefore, site C might not play an important role in the catalysis of 
Fe(II) oxidation, but could play an important role in determining iron movement into the protein 
cavity (32, 34).  
1.8 Bacterioferritin  
Bacterioferritin was first observed in E. coli whole cells, in which optical spectra indicated the 
presence of a heme containing protein that was assumed to be a cytochrome, cytochrome b1 or 
cytochrome b557.5 (35). Subsequently, a cytochrome b protein that contained a large amount of 
iron was isolated from Azotobacter vinelandii (36) and since then BFRs have been isolated from 
various bacteria such as Rhodobacter capsulatus and Desulfovibrio desulfuricans. Despite the 
fact that it contains heme, BFR is a member of the ferritin family of iron-storage proteins and 
contains 24 identical subunits that are packed together to form the typical highly symmetrical, 
nearly spherical shell surrounding a central, hollow shell, about 80 Å in diameter. The heme-
binding sites are located at the interface between the two subunits the make up each of the 12 
faces of the dodecahedron. Hence there are 12 heme-binding sites, see Figure 1.10. The hemes 
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have bis-methionine axial ligation, with the methionine residues provided by the two separate 
subunits(37). Bis-Met coordination is highly unusual, with only one other known occurrence, in 
the surface protein Shp of Streptococcus pyogene (9).  In addition to the absorption bands in the 
visible region that are highly characteristic of heme, bis-Met coordinated heme gives rise to a 
weak absorption band at ~739 nm due to a LMCT band resulting from the coordination of Met 
sulfur to iron(III) (38-40). 
As in other 24mer ferritins, the symmetrical arrangement of the subunits in BFR results in 
various channels that connect the inner core with the protein environment.  There are eight three-
fold symmetry channels, six four-fold symmetry channels and twelve B-channels formed 
between subunits that are possible entry and exit routes iron (Figure 1.7). The three-fold channel 
and the four-fold channel are both hydrophilic in BFR, being lined with Asp109, Arg117, and 
Asp118.  Since BFR and eukaryotic H-chain 3-fold channels are very similar, it has been 
proposed that these channels are the major sites used by ferrous to enter and move to the 
ferroxidase centre. However, substitution of Asp118 with Ala had a relatively minor effect on 
mineralisation (41).  The four-fold channels are also hydrophilic with four Asn148 residues on 
the outer surface of the protein shell and four Gln151 residues on the inner surface. B-channels 
are lined with Asp132, Glu135, Thr136, and Asp139 with Asn34 and Glu66 from different 
subunits. 
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Figure 1.7. The overall structure of E. coli BFR. BFR structure looking down (A) a 
three-fold (B) a four-fold and (C) a B-channel. Figure generated from PDB 1BFR. 
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1.8.1   The ferroxidase centre and inner-surface site 
 
Each BFR subunit includes a dinuclear metal binding site (the diiron site) linking together the 
four major helices of the subunit, which has been identified as the ferroxidase active site, 
responsible for catalyzing the oxidation of ferrous iron by dioxygen (2). The BFR ferroxidase 
centre is distinct from those of other H-chain subunits (see Figure 1.2B and Figure 1.8), in that it 
is highly symmetrical, projecting a much closer relationship to the centres of class II di-iron 
proteins, such as ribonucleotide reductase and methane monooxygenase (3, 42).  These structural 
differences result in distinct mechanistic and functional properties. For example, spectroscopic 
and kinetic studies showed that the oxidised form of the ferroxidase centre of E. coli BFR is 
stable and that the ferroxidase centre is required throughout core formation (2, 43). 
 
 
 
 
 
 
 
Figure 1.8.  The ferroxidase centre and inner-surface site of E. coli BFR. A 
stick/cartoon representation of the di-Fe(II) form of the E. coli and the inner-surface site 
where Fe2+ is coordinated by His46 and Asp50.  PDB 3E1M. 
 
	  Fe1	   	  Fe2	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The residues forming the di-iron (Fe1 and Fe2) centre of BFR consist of two terminal glutamates 
(Glu18 to Fe1, Glu94 to Fe2), and histidines (His55, His130), and two bridging glutamates 
(Glu51, Glu127) (Figure 1.2B). All of these residues are conserved in the BFR sub-family. The 
ferroxidase site is capable of binding metals other than iron including zinc, cobalt, and 
manganese. Studies have shown zinc is a potent inhibitor of iron oxidation activity, and this 
occurs through the binding of the metal to the dinuclear iron site (9, 41, 44). 
Besides the ferroxidase centre, E. coli BFR has been shown to possess an additional iron site, 
located on the inner surface of the protein, approximately 9.2 Å from the nearest ferroxidase 
centre iron, and 10.2 Å from the second iron, in which ferrous iron is coordinated by an aspartate 
residue (Asp50) and a histidine residue (His46) (see Figure 1.8 and 1.9). This site is structurally 
and mechanistically important; kinetic studies of variant proteins containing substitutions of 
either Asp50 or His46 exhibited significantly impaired iron mineralisation but were unaffected in 
their ferroxidase centre reaction.  The inner surface iron site is believed to be required for the 
transfer of electrons, derived from Fe
2+
 oxidation in the cavity, to the ferroxidase centre (9, 28), 
see section 1.9.2.  
 
 
 
 
 
Figure 1.9 The inner-surface site of E. coli BFR.  A cartoon representation of the inner-
surface site of E. coli in which Fe2+ is below Fe1 and Fe2. PDB 3E1M. 
Inner-­‐surface	  site	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1.8.2   Heme-binding site 
 
 
BFR is unique amongst ferritins in that it contains 12 heme-binding sites, and these sites give the 
protein a characteristic red colour. BFR heme is located at a two-fold symmetric inter-subunit 
site, where it is sandwiched between two methionine residues (Figure 1.8). The bis-methionine 
coordination leads to a ligand field strength sufficient to generate the low-spin state of the heme 
iron. Furthermore, in A. vinelandii BFR, heme has a reduction potential which is remarkably low. 
In the absence of the iron core of the protein, the heme midpoint potential has been measured at 
pH 8.0 as −225 mV (vs NHE), while in the presence of the iron phosphate core this potential 
drops to −475 mV.  The iron core has a reduction potential of -420 mV which suggests a possible 
redox interaction between the iron core and heme.  The reduction potential of the core is very 
low indicating that it is hard to reduce. However, the heme potential is lower still, suggesting that 
it is capable of passing electrons in the the core resulting in reduction of Fe(III) to Fe(II).The 
reduction potential for the iron-coproporphyrin III that replaces heme in the structure of bound to 
D. desulfuricans BFR was measured to be +140 mV which is much higher than that of A. 
vinelandii BFR (39, 45). The reduction potential of heme bound to E. coli BFR has not been 
reported. 
 
The presence of heme in BFR is an intriguing matter as heme is normally present in proteins as 
an essential cofactor. For a long time there was a lack of consensus about the functional role for 
heme in BFR. It has been reported that heme is not required for protein assembly or aerobic 
oxidative iron uptake, as similar activities were observed for a heme-free variant and the wild 
type protein (39). Heme-free E. coli BFR, obtained by substitution of the methionyl residues that 
normally bind heme with His or Leu, accumulated, in vivo, four times as much iron as compared 
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to heme bound wild-type protein.   Significant accumulations of iron led to the suggestion that 
heme functions in iron release, and there is now evidence for its involvement in iron release, 
through mediating the reduction of the iron core (9, 27, 39), see section 1.9.1. 
 
Figure 1.10. A cartoon representation of E. coli BFR subunits showing the ferroxidase 
centre, the outer and inner surfaces, and the heme-binding site.  The heme is located at 
an intra-dimer, inter-monomer site and is coordinated by two Met52 residues, one from 
each subunit PDB 1BCB. 
 
 
1.8.3   The iron mineral core  
Like eukaryotic ferritins, BFR from E. coli is able to accumulate large quantities of iron, 
theoretically up to 4500 iron atoms, in the form of an inorganic ferric oxyhyrdoxide mineral in 
the central cavity.  However, as isolated, the protein from native sources usually contains around 
800-1500 iron atoms. This might be related to the fact that BFRs are most efficient at lower iron 
loading. It has been suggested that, at high iron loadings where there is more iron around to fully 
load ferritin, the rate of mineralisation is lower due to ferrous oxidation occurring outside of the 
cavity, competing kinetically with intra-protein oxidation (10).  For example noncore oxidation 
can occur within the protein coat channels that provide access for Fe2+ into the cavity, potentially 
blocking Fe2+ access routes (9, 44).     
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The mineral cores of native BFR are generally phosphate-rich ‘iron-oxyhydroxide-phosphate’, 
though, like other ferritins, phosphate is not essential for core formation to occur. The amount of 
phosphate present in the iron core of BFR is greater than in other ferritins and the phosphate is 
dispersed throughout the core structure, giving an amorphous and much less dense structure 
compared to mammalian ferritin cores (46). Furthermore, in vitro oxidation of iron in the 
presence of phosphate allows the incorporation of phosphate into the iron core at levels found in 
native cores and changes the structural and chemical nature of the core.  
 
1.9 Mechanistic asepcts of BFR 
 
1.9.1   Mechanism of iron mineralisation  
In BFR, the ferroxidase centre plays an essential role in the mechanism of iron mineralisation 
(27).  Mineralisation of E. coli BFR occurs by three kinetically distinct phases. In the first and 
fastest phase, two Fe2+ ions enter via an outer pore to each of the flexible 24 pre-organized 
ferroxidase centres. In the presence of dioxygen or hydrogen peroxide the di-Fe2+ ions are 
oxidised to Fe3+, resulting in a likely hydroxo bridged di-Fe3+ form of the centre along with 
reduction of dioxygen to hydrogen peroxide or hydrogen peroxide to water.  This is phase 2 of 
the mineralisation process, 48 Fe(II) per 24mer, or 2 per subunits are required to saturate the 
ferroxidase centres.  Fe(II) added in excess of, 48 Fe(II) per protein leads to the formation of an  
oxyhdroxide mineral core (phase 3) in a reaction that occurs much more slowly than phase 2 
oxidation at the ferroxidase centre.   
The bridged di-Fe(III) form of the ferroxidase centre is stable.  This property makes BFR quite 
distinct from eukaryotic and bacterial ferritins, in which the oxidised form of the ferroxidase 
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centre is unstable, with Fe(III) migrating into the cavity. The stability of the oxidised BFR 
ferroxidase centre raises the question of how it functions in mineralisation.  It is apparent that the 
centre behaves as a true catalytic centre in BFR; it cycles its oxidation state between di-Fe(II) 
and bridged di-Fe(III) forms and this process drives the mineralisation reaction in the central 
cavity. Electrons necessary to re-reduce the oxidised from of the centre are derived from Fe(II) 
oxidation occurring in the cavity.  
 
 
Figure 1.11. Mechanism of mineralisation in E .coli BFR. This model displays the 
mechanism of iron uptake which consists of three distinct kinetic phases:  phase 1, 
binding of two Fe2+ ions per ferroxidase centre (FC), rapid oxidation of the Fe2+ to Fe3+ 
in the presence of dioxygen in phase 2.  Phase 3, Fe2+ bound at the internal, inner site is 
oxidised, where electrons are channeled to ferroxidase centre then re-reduced. The 
mechanism continues to operate during the core formation. 
 
Recent studies suggest that inner surface site (see section 1.8.1) is a key constituent of the 
electron transfer pathway connecting the core to the ferroxidase centre.  When Fe2+ is present in 
excess of that required to saturate the ferroxidase centre sites, it enters the central cavity, and 
binds on the inner face of the protein coat at internal nucleation sites.   In that particular site, 
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involving the side chain of Asp50 and His46, the Fe2+ is approximately 10 Å away from the 
ferroxidse centre. The Fe2+ bound at that internal surface site becomes oxidised to Fe3+ and 
eventually undergoes a hydrolysis reaction.  The electrons from Fe2+ oxidation in the cavity are 
channeled to the ferroxidase centre forming a reduced di-Fe2+of the centre.  The generated di-
Fe2+ ferroxidase centre can now react again with dioxygen/hydrogen peroxide, perpetuating a 
catalytic cycle that drives the core mineralisation process (9), see Figure 1.11 for a summary of 
the mechanism.   
In Phase 2, the presence of phosphate does not significantly affect the rate, but in Phase 3, the 
presence of phosphate significantly enhanced the rate up to five-fold (46). Phosphate is believed 
to play a role in iron binding and electron transfer at the iron core as shown by studies with A. 
vinelandii BFR (47). 
 
1.9.2   Mechanism of iron release 
As mentioned above, a major function of BFR is iron storage.  An iron store for anabolic 
processes is only useful if iron can be released from it, as required. The mechanism of how iron 
is released from the insoluble core of BFR remains unclear.  
 
As for eukaryotic ferritins, iron release from BFR requires a source of electrons and protons, and 
can be followed using the same kind of chelator assays.  Studies of E. coli BFR showed that 
chelators such as pipyridyl and ferrozine are not innocent reporters of iron release, but actually 
influence (enhance) the rate of iron release, indicating that they must interact with the protein in 
some way. The use of different reducants showed that electron transfer to the mineral core is the 
rate-determining step of the release process (27).   
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The heme groups of BFR have been proposed to be involved in iron release, but evidence for this 
has been lacking until recently.  Studies of BFR containing variable numbers of heme groups 
revealed that the presence of heme significantly enhanced the rate of iron release, consistent with 
a role for heme in channeling electrons from the reductant towards the core mineral.  Any 
enhancement in this rate would be expected to increase the overall rate of release. The identity of 
the physiological reductant for iron release is unclear, but, as for eukaryotic systems, flavins 
have been suggested as likely candidates and can certainly act as efficient reductants in vitro.  
In many bacteria, the gene encoding BFR is found next to a gene that encodes a small ferredoxin 
protein called Bfd (bacterioferritin-associated ferredoxin) and the expression of Bfd is 
upregulated under low iron conditions, suggesting that this ferredoxin might play a role in iron 
release (29, 48, 49). 
Early studies of Bfd from E. coli revealed that it binds a [2Fe-2S] cluster with a reduction-
midpoint potential of -254 mV, and that it binds specifically to BFR (50). The high resolution 
structure of a complex between P.	  aeruginosa BFR and Bfd showed that Bfd binds above the 
heme groups at an inter-subunit location, with the cluster  ~18 Å away from the heme iron (49).  
 
1.10 Goals of current study:  
1. Iron mineralisation in the recently discovered diatom PmFTN is not well understood. We 
therefore sought to investigate the catalytic mechanism of iron uptake.  This was of 
particular interest because PmFTN is the first eukaryotic ferritin with a site C located 
close to the intra-subunit ferroxidase centre (see section 1.7.1). Thus, it was expected that 
the mineralisation mechanism would be different from that of other eukaryotic ferritins.  
 
2. It was previously shown that heme plays a role in iron release from BFR.  However, the 
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previous study was restricted to samples of BFR containing zero, one or five hemes per 
BFR.  Recently, a novel method for fully loading BFR with heme after purification was 
devised (51). We sought to establish that the added heme binds at the native heme-
binding site and to generate a range of heme loaded BFR samples in order to understand 
in more detail the role of heme in iron release, and particularly the dependence on heme 
loading. 
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Chapter 2:  Materials and Methods 
 
 
2.1  Overproduction and purification of wild-type and M52H BFR 
 
2.1.1  Strains and plasmids 
Wild type BFR was expressed from cultures of E. coli AL1 (BL21 DE3 bfr –) containing the 
plasmid pALN1 (a pET21a derivative containing the bfr gene). For M52H BFR, a heme free 
variant of BFR, E. coli JM109 was transformed with pGS758, a derivative of pALTER-Ex1 
under the control of a tac promoter. 
2.1.2 Preparation of media and growth of cultures  
BFR cultures were grown at 37 oC at 200 rpm in Luria-Bertani (LB) media (10 g tryptone, 5 g 
yeast extract, 10 g NaCl per liter distilled water). On solid media, agar was added to LB (3 g per 
250 mL) prior to autoclaving, and poured into 9 cm diameter sterile plates.  After autoclaving, a 
final concentration of 100 µg/mL ampicillin was added. Each flask was inoculated with 2.5 mL 
of colonies resupsended in LB from agar plates, and grown until the optical density at 600 nm 
(OD600) was 0.4-0.8.  At this point wild-type bfr gene expression was induced with a final 
concentration of 1 mM IPTG (Isopropyl-β-D-thiogalactopyranoside) and cultures grown for a 
further 4 hours.  In the case of heme-free BFR (M52H), 0.4 mM IPTG was added and cultures 
were grown overnight. 
2.1.3 Cell harvest and disruption 
The cell cultures were harvested by centrifugation at 7,500 rpm for 15 minutes at 4 °C. The 
resulting supernatant was discarded and the pellet was resuspended  in 200 mL of BFR buffer 
(20 mM HEPES, 100 mM KCl, 0.1 mM EDTA, 10 % v/v glycerol, pH 7.8) and centrifuged as 
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before. The supernatant was discarded and the wet pellet weighed.  Where necessary, the pellet 
was stored at −70  °C until later needed.  
The cell pellets were resuspended in a minimal volume of BFR buffer (~ 10 mL per 1 g).  The 
sample was divided into 30 mL aliquots and then sonicated for 0.2 sec/sec at 100 watts for 8 
minutes 20 seconds and allowed to cool on ice before sonicating again. Cell debris were pelleted 
by centrifugation at 4 °C and 18500 rpm for 45 minutes. 
2.1.4 Crude purification steps 
The supernatant was heated for 70-80°C in a metal beaker in a water bath and stirred 
continuously for 15 minutes, then rapidly cooled by placing the beaker on ice with continuous 
stirring.  The suspension was centrifuged at 4 °C and 18500 rpm for 45 minutes.  The 
supernatant was collected and stored on ice and subsequently precipitated with ammonium 
sulphate (0.55 g/mL) at 4 °C overnight.  The resulting suspension was centrifuged as before and 
the supernatant was discarded.  The pellet was resuspended in a minimal volume of BFR buffer 
(~20 mL), and the resulting solution was dialyzed at 4 °C against 500 mL of BFR buffer, with 
three changes over 12 hours.  
2.1.5 Column chromatography  
A Sephacryl S300 (GE Healthcare) gel filtration column [70 x 1.6 cm (bed dimensions)] was 
equilibrated at 2 mL/min overnight with 3 L BFR buffer at 4 °C. The dialysed protein was 
loaded onto the column and eluted at ~2-3 mL/min using the same BFR buffer. Fractions of 10 
mL were collected using a fraction collector and analysed for BFR content by SDS-PAGE. 
A 5 mL Q-sepharose column (Amersham Biosciences) was equilibrated in five column volumes 
of BFR buffer at 1 mL/min.  Pooled fractions of BFR were loaded on to the column and the 
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protein eluted with 1 M KCl in BFR Buffer. Samples were collected in a fraction collector and 
dialyzed against 0.1 M MES, pH 6.5 at 4 °C with three changes of buffer.  
2.1.6 SDS-PAGE Analyses  
Samples were taken at various stages of cell growth, harvesting and purification for SDS-PAGE 
analysis to determine purity as shown in result section. A BioRad gel kit was used to prepare w/v 
15% SDS polyacrylamide gels.  Sample pellets were resuspended in SDS-PAGE loading buffer 
(1 M Tris pH 6.8, 200 mM DTT, 20% w/v SDS, 20% v/v glycerol, and a grain of bromopheonol 
blue), boiled for 10 minutes, and centrifuged prior to loading onto the gel.  The gel was stained 
with Coomassie blue (2.5 g Coomassie brilliant blue, 30% v/v methanol, 7% v/v acetic acid, and 
distilled water per litre), and subsequently destained in 10% v/v Methanol, 10% v/v Acetic Acid, 
and distilled water.  
2.2 Removal of iron from BFR to generate apo-BFR  
Iron was removed from BFR by utilizing sodium dithionite as reductant and 2,2’-bipyridyl as a 
chelator at 4 °C. BFR was dialyzed against 100 mM MES buffer pH 6.2 (freshly prepared in 500 
mL deoxygenated Millipore water, sparged for a minimum of 1 hour with dinitrogen) containing 
sodium dithionite (3 g/100 mL) and a spatula tip of bipyridyl.  The reduction/chelator buffer was 
exchanged 4-5 times over a period of 36 hours. The sample was then dialyzed against 500 mL 
0.1 M MES buffer, 0.5 M NaCl pH 6.2 and exchanged 3 times over 24 hours.  Finally apo-BFR 
was dialyzed against 500 mL 0.1 M MES pH 6.2 (3 changes) and 500 mL 0.1 M MES pH 6.5 (3 
changes) over a 48 hour period.  
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2.3 PmFTN Samples  
Pseudo-nitzschia multiseris ferritin protein (wild-type and variants) samples were purified and 
subjected to iron removal by Stephanie Pfaffen in the laboratory of Prof. Michael Murphy, 
University of British Columbia, Vancouver. Table 2.1 shows the samples that were supplied.  
Alkylated samples were treated as described in chapter 3.  This resulted in the following samples 
shown below.  
 
PmFTN Samples 
 
Comments  
Wild-type           Alkylated at the three Cys residues to improve protein 
stability during crystallization study. 
Wild-type   Non-alkylated samples 
Triple Cys variants Protein in which all three Cys residues were substituted 
with Ala 
E44H Alkylated at the three Cys residues to improve protein 
stability. Glu44 was replaced with His.  
E130A Alkylated at the three Cys residues to improve protein 
stability. Glu44 was substituted with Ala. 
E44Q  Non-Cys residues were substituted with Ala. Also Glu44 
was substituted with Gln. 
 
Table 2.1.  Pseudo-nitzschia multiseries ferritin samples used in the iron uptake study. 
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2.4 Protein and iron concentration determinations 
 
Protein concentrations were determined using the bicinchoninic acid (BCA) method  (Smith et 
al., 1985).  Bovine serum albumin (BSA) was used as the standard.  A calibration curve was 
attained for the BSA standard to determine the concentration of unknown protein samples.  The 
protein concentration was calculated according to the relationship shown Eq. 2.1. BFR 
concentration was also determined through absorbance at 280 nm using an extinction coefficient 
33, 000 M-1 cm-1 (2) per subunit. For PmFTN at 280 nm extinction coefficient of 24, 980 M-1 cm-
1 per subunit (30).  
        
Unknown concentration =       Gradient of unknown         x    Concentration of BSA              (Eq. 2.1) 
                                                                    Gradient of BSA  
 
Iron contents of BFR were determined using a colorimetric method. BFR samples with unknown 
iron content, at appropriate concentration (0.5 µM), were placed in 0.5 mL aliquots (in triplicate) 
into Teflon containers, followed by addition of 0.5 mL concentrated nitric acid (70 % v/v). Each 
container was sealed into a stainless steel outer jacket and placed in an oven at >100 ºC 
overnight. A series of ferrous ammonium sulphate standards with a final concentration of 50-250 
µM were also prepared from a carefully prepared 5 mM stock solution. 0.4 mL of the iron 
standard solutions were placed in labeled test tubes and 0.4 mL concentrated nitric acid was 
added. When the digested protein samples were cooled, 0.8 mL from each Teflon container was 
placed into a labeled test tube, 0. 4 mL of 252 mM sodium ascorbate was added to each test tube 
(sample and standards) followed by 2 mL of saturated sodium acetate and mixed. Finally, 0.4 mL 
of 10 mM ferrozine solution was added to each tube and the colour was allowed to develop at 
room temperature for 15 minutes. Using plastic cuvettes, absorbance at 562 nm was measured. 
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Absorbance data were plotted as a function of Fe(II) concentration to generate a standard curve. 
A line of best fit was drawn and the iron concentration of the unknown protein sample was then 
estimated from the absorbance reading for each unknown sample.  The concentration of iron was 
verified using the extinction coefficient for the [Fe(II)(ferrozine)3] complex at 562 nm (28,000 
M-1 cm-1) (52). 
 
2.5 Spectroscopic and Kinetic Analyses  
 
2.5.1 UV-visible absorbance spectroscopy  
This technique involves measurement of electronic transitions of samples from their ground state 
to various excited states. The energy required to promote such transitions lies in the ultraviolet 
UV (200-400 nm) and visible (400-750 nm) regions of the spectrum. Different types of 
molecules absorb different frequencies of light providing a means by which they can be 
distinguished. Types of transitions include π è π*, and n è π*(promotion of a non-bonding or 
lone- pair electron to π*). These types of transitions occur in the peptide backbone of proteins 
and in aromatic amino acid side chains. The d-d and charge-transfer (CT) transitions are also 
common and are usually highly characteristic of protein cofactors. UV-Visible absorbance is a 
quantitative technique where absorbance intensity is related to concentration through the Beer-
Lambert law, Equation 2.2. 
 
A  =  log (Io/It )  =  ε . c . l                                                                             (Eq. 2.2) 
 
Here A is absorbance (with no units); Io  and  It  are, respectively, the radiation incident on, and 
transmitted by, the sample;  ε   is the extinction coefficient (measured in units of M-1 cm-1);  c  is 
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the molar concentration of the sample (M); and  l  is the pathlength (cm) of the sample through 
which the radiation travels.  This enables changes during reactions to be followed quantitatively. 
 Iron uptake measurements were carried out using a Perkin Elmer λ35 or λ800 UV-visible 
spectrophotometer by following absorbance changes at 340 nm after addition of ferrous iron as a 
function of time. Data attained were plotted using Origin software (version 7.0 Origin Labs).  
Increases of absorbance at 340 nm are due to the oxidation of ferrous to ferric iron, resulting in 
ligand to metal CT bands in the near UV-and visible regions. 
2.5.2 Stopped-flow experiments   
 
 
Fast biochemical reactions that take place in solution over timescales of milliseconds up to tens 
of seconds are difficult to follow accurately using a conventional spectrophotometer.  However, 
by using rapid mixing stopped-flow, fast reactions can be precisely measured. In the stopped-
flow spectrophotometer, two reactants are rapidly mixed in a mixing chamber (approximately 
100-200 µL). The flow is stopped with the reactant stream in the flow cell.  At this point data 
accumulation in the observation cell begins and changes in absorbance or fluorescence are 
followed over time. A schematic representation of the stopped flow is shown in Figure 2.1.  
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Figure 2.1. Schematic diagram of a stopped-flow instrument.   
 
In this study, rapid changes in absorption at 340 nm and >500 ms after the addition of ferrous 
solution to PmFTN were measured using an Applied Photophysics DX17MV stopped-flow 
instrument. The collected data was processed by the supplied software and absorbance versus 
time data files exported into Origin (version 7, Origin Labs) for plotting, fitting and presentation. 
Data curves were fitted using Origin, either to single or double exponent.  
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2.5.3 Addition of heme to BFR 
In overexpressed purified BFR less than stoichiometric amounts of heme are bound to the protein. 
The numbers of hemes bound to the protein was determined from the absorbance at 280 nm (33, 
000 M-1 cm-1 per subunit) and at 418 nm (109,000 M-1 cm-1per heme) (53) with the extinction 
coefficient indicated. In order to achieve full occupancy of the heme-binding sites, heme was 
added to the protein. Stock solutions of 1 mM hemin chloride (Sigma) were prepared by 
dissolving hemin chloride in sodium hydroxide (5 M) and diluting with 50 mM Tris-HCl, 50 mM 
KCl pH 8 buffer, and quantified by using extinction coefficient, ϵ385 nm = 55000 M−1 cm−1.  After 
hemin addition to the protein (0.5 µM) in 0.1 M MES pH 6.5, 1 M NaCl the solution was heated 
to 80 °C for 10 mins, and allowed to cool to room temperature.  Free and adventitiously bound 
hemes were removed from the protein by passage through a PD-10 desalting column (GE 
Healthcare), equilibrated with 0.1 M MES, pH 6.5. Absorbance changes were measured using a 
Jasco 2100 UV-visible spectrophotometer.  In the case of M52H BFR, addition of heme to the 
protein, according to the method described above, led to precipitation of ~25-33 % of the protein 
when heated at 80 °C.  Therefore, it was instead heated to 65 °C. 
 
2.5.4 Addition of Fe(II) to apo-ferritin 
To mineralize apo-ferritin, a solution of ferrous ammonium sulfate was prepared in 
deoxygenated pure water (sparged with nitrogen gas for a minimum of 3 hours).  Concentrated 
hydrochloric acid (25 µl/50 mL) was added to prevent auto-oxidation of Fe(II).  A micro-syringe 
(Hamilton) was used to make microlitre additions of the iron stock solution to a cuvette 
containing aerobic solutions of 0.5 µM BFR (wild type, heme loaded and heme free variant) or 
PmFTN (wild-type and variants) in 100 mM MES, pH 6.5 at 25 °C. Kinetics of the core 
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formation process were determined by measuring A340nm changes. Fe(II) oxidation was allowed 
to go to completion and the resulting solution was transferred to an Eppendorf tube and 
centrifuged at 10, 000 rpm for 5 min to remove any Fe(III) precipitate not bound to the protein. 
The supernatant was carefully transferred back into the cuvette prior to the next addition. 
Absorbance changes were measured using a PerkinElmer λ800 spectrophotometer. 
2.5.5 Fe(II) oxidation rate analysis  
In order to determine kinetic characteristics of mineralisation (Phase 3), Fe(II) oxidation, rates 
were calculated by drawing a tangent line (shown in Figure 2.2) to the initial linear region of the 
curve or slope, corresponding to the initial rate of oxidation.  The slope of the tangent was 
calculated, giving the rate. 
 
Figure 2.2. Rate calculation of Fe(II) oxidation in µMs-1. 
 
Calculated rates, in units of ΔA at 340 nm per second, were converted to µM Fe(II) oxidised per 
second by dividing by the total ΔA340nm which corresponds to the complete oxidation of a known 
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concentration of Fe(II), and multiplying by that Fe(II) concentration, giving the rate in units of 
µM s-1 (see Eq. 2.4).  Estimates of the error in the determined rates were obtained by drawing 
alternative tangents describing the outermost acceptable fits of the data, calculating rates and 
determining standard errors (46).  
                      
Rate =             (Δ A340 / Total Δ A340)    x    Fe (II) concentration                (Eq. 2.4) 
Δt 
2.5.6 Release of Iron from the Core  
To study the release of iron, BFR loaded with 1200 Fe(II) was transferred to an anaerobic 
cabinet (Faircrest) in which O2 was maintained at <3.0 ppm, unless otherwise specified. Stock 
solutions of 50 mM sodium dithionite were prepared and quantified anaerobically by utilizing 
the extinction coefficient, ϵ320 nm = 8000 M−1 cm−1 (54). A mixed buffer system (referred to as 
MBS: potassium acetate, MES, Tris, MOPS (all at 10 mM), 200 mM NaCl, pH 6 or 7) was used, 
and iron release was monitored using the Fe2+ chelator ferrozine (3-[2-pyridyl]-5,6-diphenyl-
1,2,4-triazine-4,4′-disulfonic acid).  The progress of the reaction was monitored by following the 
time-dependent changes in the intensity of the band at 562 nm reporting on the formation of 
[Fe(II)(ferrozine)3]4− (ϵ562 nm = 28,000 M−1 cm−1) (52), indicative of Fe2+ release. In most cases, 
the chelator was present at 1 mM and BFR was present at 0.05 µM (containing 1200 Fe3+), and 
assays were conducted in a 1.0 cm path length cuvette equipped, and release initiated by the 
addition of sodium dithionite via a microsyringe (Hamilton). For iron release experiments with 
flavin mononucleotide (FMN), generation of the reduced dihydroflavin form (FMNH2) was 
carried out using stoichiometric or excess concentrations of sodium dithionite. Assays in MBS 
were performed at pH 7.0 and 15 °C, with chelator, dithionite (100 µM), and variable FMN (0–
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100 µM) (27). Absorbance changes were measured using a PerkinElmer λ800 spectrophotometer. 
Data were fitted to a single exponential function, yielding a first order rate constant, 
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Chapter 3: Mechanistic studies of iron uptake by a pennate diatom 
ferritin 
 
3.1 Study of iron uptake in PmFTN 
A novel ferritin was recently discovered in Pseudo-nitzschia multiseries, a marine pennate 
diatom that is found in algal blooms, which result from periodic iron deposition from 
atmospheric dust and flow from the deep ocean.  Diatoms play a major role in global primary 
production and carbon sequestration to the deep ocean. Storing iron in ferritin is one mechanism 
that confers a growth advantage, enabling those that contain a ferritin to better survive the low 
iron conditions that normally prevail in the oceans. Ferritin from the diatom, referred to as 
PmFTN, is structurally similar to other eukaryotic ferritins. Three distinct iron binding sites were 
identified.  Sites A and B are located at the conserved ferroxidase active site.  The centre is 
unusual, however, as it contains a third iron site (site C) previously found only in non-heme 
prokaryotic ferritins. The mechanism of iron mineralisation is not been investigated.  During the 
preparation the cysteine residues were alkylated to improve protein stability.  Here, rapid 
reaction kinetic studies of alkylated and non-alkylated PmFTN were undertaken.  
3.2 Iron core formation in PmFTN 
To examine the protein’s ability to store iron, the mineralisation reaction of alkylated wild-type 
PmFTN was studied by following changes in absorbance at 340 nm upon addition of 400 Fe(II) 
per apo-PmFTN molecule, see Figure 3.1.  Mineralisation involves the binding and oxidation of 
iron at the inner core, and only occurs (to any significant extent) where Fe(II) exceeds that 
required to saturate the ferroxidase centre and associated sites. The trace in Figure 3.1 shows 
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clearly that the PmFTN protein is able to catalyse Fe(II) oxidation.  Phase 2 is not observed, due 
to the experimental set up. 
 
Figure 3.1. Absorbance changes at 340 nm showing Fe(II) oxidation in the presence of  
alkylated 0.5 µM PmFTN in 0.1 MES pH 6.5. 400 Fe(II) ions per PmFTN were added at 
25 °C and pathlength 1 cm.  
 
To examine the protein’s capacity to store iron, sequential additions of 400 Fe(II) per protein 
were made to apo-PmFTN see Figure 3.2A. Precipitation was observed in the cuvette after the 
addition of a total of 1600 Fe(II) ions per PmFTN. The second addition of Fe(II) is oxidised but 
at a rate that is clearly lower than that for the first addition, and the rate does not increase for 
subsequent additions. Little of the third addition is actually taken up by the protein (as 
demonstrated by the large decrease in absorbance following centrifugation of the sample after 
the third addition).  Thus, the protein does not have a high capacity for iron, at least under the 
conditions tested here.  Figure 3.2B shows a plot of the initial rate of Fe(II) oxidation as a 
function of Fe(II) ions added per PmFTN.  It shows a maximum rate at 400 Fe(II) ions.  This is 
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quite different behaviour to ferritins such as BFR, which exhibit a maximum rate at ~1200 Fe(II) 
per protein, and can accommodate 2700 Fe(II) per protein (44). Furthermore, each addition of 
400 Fe(II) ions produces a larger absorption response than the previous addition. This does not 
occur with BFR and could indicate that the form of the mineral core changes significantly during 
the course of the titration. 
 
 
 
 
 
 
 
 
Figure 3.2.  Iron oxidation catalysed by alkylated wild-type PmFTN. (A) Absorbance 
changes at 340 nm showing Fe(II) oxidation in the presence of 0. 5 µM PmFTN in 0.1 
MES pH 6.5.  Numbers indicate total Fe(II) ion additions (sequentially added 400 Fe(II) 
ions per PmFTN) at 25 °C and pathlength 1 cm. (B) Plot of initial rate of Fe(II) 
oxidation, catalysed by 0.5 µM PmFTN in 0.1 MES pH 6.5, as a function of Fe(II) ions 
added per PmFTN. Rates were calculated as described in chapter 2.  
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3.3 Iron oxidation kinetics at the ferroxidase centre 
To monitor rapid Fe(II)  oxidation catalysed by apo-PmFTN, stopped-flow experiments were 
performed monitoring absorption changes at 340 nm. Figure 3.3 shows absorption changes 
following mixing of 1 µM alkylated wild-type apo-PmFTN in 0.1 M MES buffer at pH 6.5, with 
various amounts of Fe(II) as function of time. An extremely rapid oxidation of Fe(II) was 
observed, the oxidation being completed within 0.5 seconds.  
For the alkylated protein, a plot of ΔA340 nm versus Fe(II)/protein, Figure 3.3B, shows that 
saturation of the initial rapid phase occurred at ~50 Fe(II) ions per protein, which is ~2 
equivalents of Fe2+ per PmFTN subunit. This amount of iron corresponds to the number of iron 
atoms required to occupy the dinuclear iron sites. This is consistent with the characteristic of 
ferritins where the ferroxidase centre is the initial site of rapid Fe(II) oxidation.   
 
 
 
 
 
 
 
	   52	  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3. Kinetic analyses of Fe(II) oxidation catalysed by alkylated wild-type 
PmFTN (A) Fe(II) was added to final concentrations of 0, 9, 18, 23, 27, 36, 45, 54, 68 
and 90 µM to PmFTN wild-type alkylated protein (1 µM) in MES buffer (0.1 M, pH 6.5, 
25 °C) using a stopped-flow instrument. (B) Final absorbance change after 0.5 seconds 
of iron oxidation at various ratios of Fe(II)/PmFTN subunit concentration. The two clear 
phases are highlighted, intersecting at ~50 Fe(II) per protein, represented by the dotted 
line.   
 
 
Figure 3.4A shows the absorption changes following the mixing of 1.2 µM non-alkylated wild-
type apo-PmFTN, in 0.1 M MES buffer at pH 6.5, with various amounts of ferrous iron as a 
A	  
	  
	  B	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function of time. Similar to alkylated-wild type it shows a very fast rapid oxidation of ferrous ion. 
For the non-alkylated protein, a plot of versus Fe(II)/protein, Figure 3.4B, shows that saturation 
of the initial rapid phase occurred at ~59 Fe(II) ions per protein, which is ~2 equivalents of Fe2+ 
per PmFTN subunit which is similar to alkylated protein.  
The t1/2 for the oxidation reaction was <50 ms, indicating that the a rate of reaction is an order of 
magnitude greater than those measured for EcFtnA and Human H ferritin under equivalent 
conditions (33, 55). Data from the alkylated and non-alkylated PmFTN(Figure 3.5A and Figure 
3.6A ) fitted well to a single exponential function, providing for each trace, an observed (pseudo-
first order) rate constant, ko. Figure 3.5B and Figure 3.6B show a plot of ko as a function of Fe(II) 
concentration. Interestingly, there is a linear relationship, demonstrating a first order dependence 
of the rate of oxidation on the concentration of Fe(II). This observation is significant because it 
indicates that Fe(II) binding, rather than Fe(II) oxidation, is the rate-determining step of the 
reaction, consistent with the unprecedented overall rate of Fe(II) oxidation. For alkylated wild-
type PmFTN (Figure 3.4B) the slope of the line provides an apparent second order rate constant, 
k, of 2.59 (+0.12) x 105 M-1 s-1 . For the non-alkylated wild-type PmFTN the slope of the line 
gives an apparent second order rate constant, k, of 5.61 (+0.02) x 105 M-1 s-1 (Figure 3.6B).  This 
approximate two-fold increase in the second order rate constant suggests that alkylation of the 
protein may have a minor effect on the ferroxidase activity of this protein.  
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Figure 3.4. Kinetic analyses of Fe(II) oxidation catalysed by non-alkylated wild-type 
PmFTN (A) Fe(II) was added to final concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80 
and 100 µM to PmFTN wild-type alkylated protein (1.2 µM) in MES buffer (0.1 M, pH 
6.5, 25 °C) using a stopped-flow instrument. (B) Final absorbance change after 0.5 
seconds of iron oxidation at various ratios of Fe(II)/PmFTN subunit concentration. The 
two clear phases are highlighted, intersecting at ~59 Fe(II) per protein, represented by 
the dotted line.   
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Figure 3.5. Kinetic analyses of Fe(II) oxidation catalysed by alkylated wild-
typePmFTN (A) Final absorbance change after 0.5 seconds of iron oxidation at various 
ratios of Fe(II)/PmFTN subunit concentration. Each trace was fitted to a single 
exponential function.  (B) Plot of observed (pseudo-first order) rate constants, obtained 
from fitting the data in Figure 3.3A, as a function of Fe(II) concentration.  A linear fit of 
the data is drawn in.  
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Figure 3.6. Kinetic analyses of Fe(II) oxidation catalysed by non-alkylated wild-
typePmFTN (A) Final absorbance change after 0.5 seconds of iron oxidation at various 
ratios of Fe(II)/PmFTN subunit concentration. Each trace was fitted to a single 
exponential function.  (B) Plot of observed (pseudo-first order) rate constants, obtained 
from fitting the data in Figure 3.4A, as a function of Fe(II) concentration.  A linear fit of 
the data is drawn in.  
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Figure 3.7 shows absorbance changes for alkylated (3.7A) and non-alkylated (3.7B) following 
addition of Fe(II) with measurement over a much longer time period.  The data demonstrate that 
absorbance changes continue to occur once the initial rapid ferroxidase centre reaction is 
complete.  Above a level of 50 Fe(II)/protein, this is due to the slower oxidation of Fe(II) present 
in the excess of that required to saturate the ferroxidase centre.  However, absorbance changes 
also occur below this level, suggesting that further changes in structure occur following 
oxidation.   
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Figure 3.7. Kinetic analyses of Fe(II) oxidation catalysed by alkylated (A) and non-
alkylated (B) wild-type PmFTN measured over a longer time period.  Variable Fe(II) 
was added (as indicated) to apo-PmFTN wild-type alkylated (1 µM) and non-alkylated 
(1.2 µM) proteins in MES buffer (0.1 M, pH 6.5, 25 °C) using a stopped-flow 
instrument.  
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3.4 Regeneration of rapid oxidation in PmFTN 
While all ferritins contain a catalytic centre (the ferroxidase centre) that promotes Fe(II) 
oxidation, ferritins differ in terms of precisely how their ferroxidase centres catalyse 
mineralisation. In some cases, the di-Fe(III) form of the centre is unstable leading to vectorial 
transfer of Fe(II) into the protein cavity where it is incorporated into the growing mineral (8). In 
others, the di-Fe(III) form is stable and the centre functions as a redox active catalytic centre that 
cycles between di-Fe(II) and di-Fe(III) states.  It was of great interest to determine how the 
ferroxidase centre of PmFTN behaves following Fe(II) oxidation.  If Fe(III) at the ferroxidase 
centres is labile and such that  the centre empties of iron following oxidation, it would be 
expected that the rapid phase of Fe(II) oxidation would be repeatedly observed.  To test this, 
alkylated PmFTN was loaded with 48 Fe(II) per 24mer in the presence of O2 and then 
subsequently incubated for 30 minutes or 20 hours.  Then, a further aliquot of Fe(II) (either 40 or 
80 Fe(II) per protein) was added and changes in A340 nm were measured. Figure 3.8A shows 
changes in A340 nm over 100 seconds after incubation for 30 minutes. Clearly, rapid oxidation 
is not seen.  Furthermore, oxidation is not complete even over the course of 1000 seconds as 
shown in Figure 3.8B. Samples that were incubated for 20 hours between additions of Fe(II) 
showed similar behaviour to the 20 minutes incubation samples (the data for 20 hours not shown 
here). Two distinct phases are observed, though it is not clear what they correspond to.  Clearly, 
the ferroxidase centre did not regenerate an apo-form following oxidation of the initial addition 
of ferrous iron.  
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Figure 3.8. Kinetic analyses of Fe(II) oxidation catalysed by alkylated wild-type 
PmFTN. (A) and (B) stopped-flow measurements of absorbance changes at 340 nm 
following the addition of 40 or 80 Fe(II) ions per protein to a sample of PmFTN 
previously treated with 50 Fe(II) per protein under aerobic conditions. The incubation 
time between Fe(II) additions was 30 min.  1 µM PmFTN was in 0.1 M MES pH 6.5. 
 
 
Non-alkylated wild-type PmFTN was also investigated in an equivalent set of experiments.  
Figure 3.9A shows changes A340 nm over 100 seconds after incubation for 30 minutes. Again, 
rapid oxidation is not seen, and oxidation is not complete even over 1000 seconds as shown in 
A	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Figure 3.9B. Incubation over 20 hours between iron additions (not shown) showed similar 
behaviour. The data show that the ferroxidase centre did not regenerate to an apo-form following 
Fe(II) oxidation.  Again, there is only a small difference in behaviour between alkylated and non-
alkylated samples.  
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Kinetic analyses of Fe(II) oxidation catalysed by non-alkylated wild-type 
PmFTN. (A) and (B) stopped-flow measurements of absorbance changes at 340 nm 
following the addition of 40 or 80 Fe(II) ions per protein to a sample of PmFTN 
previously treated with 50 Fe(II) per protein under aerobic conditions. The incubation 
time between Fe(II) additions was 30 min.  1 µM PmFTN was in 0.1 M MES pH 6.5. 
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3.5 The formation of di-Fe(III) peroxo complex formation 
In some ferritins, particularly eukaryotic proteins, a di-Fe(III) peroxy species, formed upon 
transfer of one electron from each Fe(II) to bound O2, can be observed through a characteristic 
transient blue colour (giving absorbance at ~650 nm) (25, 56). Thus, it was of interest to 
determine whether such a species can be detected during rapid Fe(II) oxidation at the ferroxidase 
centre of PmFTN.   Stopped-flow spectrophotometry was used to monitor changes in absorbance 
at 650 nm. Figure 3.10A shows 650 nm absorbance changes following mixing the apo-protein 
with 48 Fe(II) per protein and was monitored to 0.5 seconds where there is no decay of the 
intermediate. In fact, the intermediate remains even at 2 seconds as shown in Figure 3.10B.  In 
order to check that this absorbance increase does not result from a broad band with a maximum 
in the 340 nm region, absorbance changes were also measured at 500 nm, see Figure 3.11.  Very 
low intensity changes are observed that are significantly weaker than those measured at 650 nm.  
Therefore, the band cannot be due to tailing absorbance from the near uv/blue visible region.  
Data from alkylated PmFTN (Figure 3.10A) fitted well to a double exponential function, 
providing a rate constant of 170.1 s-1 (+0.0002). This rate constant is higher than that for Fe(II) 
oxidation which is ~25 s-1.  These rate constants were obtained under different experimental 
conditions, so cannot be compared directly.  However, the data are consistent with the process at 
650 nm occurring more rapidly than the appearance of Fe(III)-O species.   
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Figure 3.10. Stopped-flow kinetic measurements of the formation and the decay of the 
µ–peroxodiferric intermediate following the absorbance changes at 650 nm after the 
addition of 48 Fe(II) ions per protein to a sample of PmFTN at 0.5 seconds (A) and at 2 
seconds (B) 5.94 µM alkylated wild-type PmFTN in 0.1 M MES pH 6.5. 
 
 
A 
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Figure 3.11. Stopped-flow kinetic measurements at 500 nm after the addition of 48 
Fe(II) ions per protein to a sample of PmFTN (5.94 µM) alkylated wild-type PmFTN 
was in 0.1 M MES pH 6.5. 
 
3.6 Dicussion  
Ferritin are important iron storage and detoxification proteins that are widely distributed in living 
kingdoms.  A ferritin recently found in a marine pennate diatom, unusually possesses a 
ferroxidase site and a site C and was therefore of interest. In the present study, it is shown that 
PmFTN can store iron and kinetic measurments of iron oxidation showed an exceedingly rapid 
initial oxidation phase involving the binding and oxidation of two Fe(II) ions per subunit.  To 
facilitate crystallization of the PmFTN protein, cysteine residues of the protein were alkylated to 
prevent oxidation. There was no significant variation in behaviour between PmFTN with 
alkylated and non-alkylated cysteine residues. The ferroxidase centre oxidation reaction is a 
second order reaction that is dependent on the concentration of Fe(II), indicating that iron 
binding and oxidation are closely linked such that they cannot be easily distinguished. Since 
oxidation occurs immediately after Fe(II) binding to PmFTN, the binding event can be viewed as 
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the slow step of the reaction. This finding is in contrast to previous reports of ferritins, in which 
binding and oxidation are considered to be kinetically distinct phases with oxidation occurring 
much more slowly (28). Measurement of Fe(II)-binding kinetics is not generally straightforward.  
In E. coli BFR the presence of heme groups facilitated detection of Fe(II) binding, as it caused a 
perturbation of absorbance due to the heme, enabling iron binding and oxidation steps to be 
distinguished, revealing that Fe(II)-binding occurred on a much shorter timescale than the 
subsequent Fe(II) oxidation (57). In comparison, Fe(II) binding to BFR occurred with a second 
order rate constant of 2.5 × 105 M-1 s-1 (at 30 °C) (58), a value similar to that measured here (at 
25 °C) for PmFTN catalysed Fe(II) oxidation. 
A previous study has shown that the ferroxidase centre reaction of PmFTN consumed dioxgen in 
a ratio of 1.9 ± 0.2 Fe(II):O2 (30). Furthermore, addition of catalase to the assay solution resulted 
in the stoichiometric regeneration of one O2, per two original diFe(II) centres, indicating the 
production of H2O2 by the ferroxidase reaction, as seen with many ferritins, (30) but not with 
BFR (20) or DPS ferritin (2). This is diferent to the oxidation stoichiometry of E. coli FtnA, in 
which the Fe(II):O2 consumption ratio was 3-4 (55). This was found to be due to the binding of 
three iron atoms, two at the ferroxidase centre and one at the site C (and a potential fourth iron at 
an unknown metal site) leading to the reduction of O2 to water instead of H2O2. The E. coli FtnA 
ferroxidase reaction is similar to that seen in human H-chain ferritin, yet is more complex due to 
present of the third iron in site C (33). However, in E. coli FtnA site C is not required for 
ferroxidase activity; studies of site C variants showed only a slight decrease in the overall 
oxidation rate with a change in the Fe(II):O2 ratio to 2.  The data presented here showed that only 
two Fe(II) ions are initially bound and oxidised per PmFTN subunit and site C is not occupied 
during the initial oxidation reaction. An important structural difference in PmFTN is that site C is 
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only 3.5-3.7 Å from site B, compared to 7-8 Å in EcFtnA. Also, a third iron binding site was 
detected site in EcBFR and human mitochondrial ferritin (59, 60).  However, these iron sites 
were seen to be at the inner surface and are more likely involved in the nucleation/mineralisation 
reaction rather than in ferroxidase centre catalysed iron oxidation (61).  
PmFTN crystals soaked in Fe(II) solution under anaerobic conditions revealed that site A is 
occupied by ferrous iron (30).  Soaking experiment under aerobic conditions showed that iron is 
observed at all three sites in a time-dependent manner.  The data from crystallographic studies 
demonstrates that, in the absence of O2, Fe(II) only binds at site A of the ferroxidase centre.  
Occupation of sites B and C occurs only following oxidation of Fe(II) to Fe(III). The stopped-
flow data presented shows saturation of the rapid phase 2 at a level of two Fe(II) ions per 
monomer of PmFTN.  Together these results indicate a likely stepwise binding of the Fe(II) and 
O2 to ferroxidase sites. A possible mechanism is one in which ferrous iron binding to site A is 
followed by the binding of the oxidant. Binding of the second ferrous iron to site B, occurs only 
when O2 is bound. A similar mechanism was proposed for the two Dps proteins from B. 
anthracis. They are mini-ferritins with a 12mer structure that contains inter-subunit dinuclear 
ferroxidase centres that are distinctive from those of maxi-ferritin 24mers, but regardless share 
some common features (62). Such a mechanism accounts for the observed rate dependence, 
because once the second Fe(II) binds, oxidation can occur  immediately. Therefore, Fe(II) 
binging to site B of the ferroxidase site is suggested to be the rate determining step, with binding 
and oxidation events intimately connected.  
So far two general models have been suggested for the mechanism of iron uptake in ferritins.  In 
the first model, as observed in human H ferritin (63), EcFtnA (64), and frog M ferritin (65), the 
ferroxidase site function as a substrate site.  Fe(II) ions binds to the ferroxidase site, becomes 
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oxidised and the resulting Fe(III) ion rapidly migrates to the mineral core. In the second model, 
the ferroxidase site is a stable di-iron site that functions as a cofactor after the binding of two 
equivalents of Fe(II) ion per subunit, as seen in EcBFR (59) and P. furiosus ferritin (66). The 
ferroxidase site functions exclusively in oxygen or peroxide reduction, and additional Fe(II) ions 
are then added directly to the mineral core and oxidised with resulting electrons re-reducing the 
ferroxidase centre. Recently, it was suggested that a unifying mechanism, in which the Fe(III) 
product at the ferroxidase site remains bound to the ferroxidase site but is rapidly displaced by 
incoming Fe(II) could account for the behaviour of all ferritins (67). This unifying mechanism 
could possibly explain the observation of a fully Fe(III) loaded ferroxidase site in crystals after 
an extended soaking in Fe(II) (57). However, the ferroxidase site of PmFTN was not fully 
occupied after soaking aerobic crystals in ferrous iron for 45 min, suggesting that iron movement 
occurred at the ferroxidase site during iron loading with 2 mM ferrous iron over prolonged time 
period (57). Immediately following oxidation of Fe(II) at the ferroxidase centre small absorbance 
changes were observed which are consistent with the idea that the di-Fe(III) from of the centre is 
unstable, leading to occupation of site C. The rapid ferroxidase centric-catalysed oxidation of 
ferrous iron in PmFTN was not regenerated upon incubation up to 20 hours, specifying that at 
least some iron remains present at the ferroxidase site. Thus, if Fe(III) is displaced, the 
subsequent iron oxidation is much slower than the initial oxidation. The mechanism of 
mineralisation in PmFTN appears to be more complex than either of the two general mechanisms 
outlined above with partial iron migration to the core.  The two distinct kinetic phases observed 
after the second addition of 48 Fe(II) iron may also be associated with slow iron migration to the 
core, likely involving the third iron binding site (site C). In frog ferritin, the transit of Fe(III) 
from the ferroxidase centre to the cavity has been observed to occur via a pathway through the 
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subunit towards a four-fold channel (26). Site C may function to direct Fe(III) along a different 
path to the mineral core.  
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Chapter 4: Mechanistic studies of iron mineralisation variants of 
diatom ferritin 
 
4.1 Non-Cys variant of PmFTN 
Protein crystallography required alkylation of free accessible Cys thiol residues to prevent slow 
oxidation. An alternative to alkylation is simply to removes the Cys residues altogether.  A 
variant of PmFTN was generated, in which all three naturally occurring Cys residues are 
replaced with Alanine.  The properties of such a non-Cys variant of PmFTN are examined here.  
To examine the capacity of the non-Cys variant of PmFTN to store iron, sequential additions of 
400 Fe(II) ions to PmFTN were made.  Figure 4.1A shows absorbance changes at 340 nm as a 
function of time following sequential additions of 400 Fe(II) ions to apo non-Cys PmFTN. 
Precipitation was observed in the cuvette after the addition of a total of 1600 Fe(II) ions per 
PmFTN. Figure 4.1B shows a plot of the rate of Fe(II) oxidation as a function of Fe(II) ions 
added per non-Cys PmFTN.  It shows a maximum initial rate at around 800 Fe(II) ions, which is 
different from alkylated wild-type PmFTN, which shows a maximum initial rate around 400 
Fe(II) ions.  
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Figure 4.1. Iron mineralisation in non-Cys PmFTN. (A) Absorbance changes at 340 nm 
showing Fe(II) oxidation in the presence of 0. 5 µM PmFTN in 0.1 MES pH 6.5.  
Numbers indicate total Fe(II) ion additions (sequentially added 400 Fe(II) ions per 
PmFTN) at 25 °C and pathlength 1 cm. (B) Plot of rate of Fe(II) oxidation, catalysed by 
0.5 µM PmFTN in 0.1 MES pH 6.5, as a function of Fe(II) ions added per PmFTN.  
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4.1.1 Fe(II) oxidation kinetics at the ferroxidase centre 
A stopped-flow instrument was used to measure the kinetics of Fe(II) oxidation after addition of 
ferrous ammonium sulphate to apo-non-Cys PmFTN by monitoring absorption change at 340 nm. 
Figure 4.2 shows the absorption changes following the mixing of 1.2 µM apo-non-Cys PmFTN, 
in 0.1 M MES buffer at pH 6.5, with various amounts of ferrous iron as function of time, as 
indicated. An extremely rapid oxidation of ferrous ion was observed similar to wild-type 
alkylated and non-alkylated PmFTN (see chapter 3), the oxidation being completed within 0.5 
seconds. Similar to the wild-type protein a clear saturation is seen as the change in absorbance at 
340 nm reaches a maximum when ~55 Fe(II) ions per protein, i.e. ~2 equivalents of Fe2+ per 
PmFTN subunit are added (Figure 4.2B). Each of the kinetic traces at 340 nm fitted well to a 
single exponential function (Figure 4.2C) providing an observed (pseudo-first order) rate 
constant, ko. Figure 4.2D shows a plot of ko as a function of Fe(II) concentration. As in the case 
of wild-type (alkylated) PmFTN , there is a linear relationship, demonstrating a first order 
dependence of the rate of oxidation on the concentration of Fe(II). This indicates that Fe(II)-
binding, rather than Fe(II) oxidation, is the rate-determining step of the reaction.  The data for 
non-Cys PmFTN, Figure 4.2D, gives an apparent second order rate constant, k, of 6.70(+0.25) x 
105 M-1 s-1, which is slightly higher than that for the alkylated wild-type protein.  
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Figure 4.2. Kinetic analyses of Fe(II) oxidation catalysed by non-Cys PmFTN (A) Fe(II) 
was added to final concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80 and 100 µM to 
PmFTN non-Cys (1.2 µM) in MES buffer (0.1 M, pH 6.5, 25 °C) using a stopped-flow 
instrument. (B) Final absorbance change after 0.5 seconds of iron oxidation at various 
ratios of Fe(II)/PmFTN subunit concentration. The two clear phases are highlighted, 
intersecting at ~55 Fe(II) per protein, represented by the dotted line.  (C) Fitting of 
PmFTN-catalysed Fe(II) oxidation data.  Each of the A340 nm traces corresponding to 
additions of 8 – 81 Fe(II) ions per PmFTN were fitted to a single exponential 
function.The solid line fits are shown along with the data from part A. 
 (D) Plot of observed (pseudo-first order) rate constants, obtained from fitting the data 
in A, as a function of Fe(II) concentration.  A linear fit of the data is drawn in.   
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4.1.2 Regeneration of rapid oxidation in PmFTN 
To examine whether the extremely rapid oxidation of Fe(II) observed upon addition of 48 Fe(II) 
per PmFTN can be regenerated, non-Cys PmFTN was loaded with 48 Fe(II) per 24mer in the 
presence of O2 and then subsequently incubated for 30 minutes or 20 hours.  Then, a further 
aliquot of Fe(II) (either 41 or 83 Fe(II) per protein) was added and changes in A340 nm were 
measured. Figure 4.3A shows changes A340 nm over 100 seconds after incubation for 30 
minutes. Clearly, rapid oxidation is not seen.  Furthermore, oxidation is not complete even over 
1000 s as shown in Figure 4.3B. The incubation over 20 hours showed similar behaviour to the 
30 minutes incubation (not shown). Two distinct phases are observed. As for (alkylated) wild-
type protein, it is not clear what they correspond to.  Clearly, the ferroxidase centre did not 
regenerate an apo-form following oxidation of the initial addition of ferrous iron, similar to wild-
type alkylated and non-alkylated PmFTN.  
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Figure 4.3. Kinetic analyses of Fe(II) oxidation catalysed by non-Cys PmFTN. (A) and 
(B) stopped-flow measurements of absorbance changes at 340 nm following the addition 
of 41 or 83 Fe(II) ions per protein to a sample of PmFTN previously treated with 50 
Fe(II) per protein under aerobic conditions. The incubation time between Fe(II) 
additions was 30 min.  1.2 µM PmFTN was in 0.1 M MES pH 6.5.  
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4.2 Variations of PmFTN at site C  
To discover more about the mechanism of mineralisation in the diatom ferritin, and particularly, 
the role of site C, a number of site-directed variants were generated (by the Murphy Lab, 
Department of Microbiology and Immunology, University of British Columbia, Canada) for 
kinetic studies. These were: E44Q (non-Cys), E44H and E130A (both alkylated).  Glu44 
coordinates iron at site C.  Substitution of Glu with Gln is intended to test for the importance of 
the negative charge at site C, while substitution with His is intended to explore the flexibility of 
coordination at site C.  Glu130 is observed to coordinate iron at both site B and site C, usually as 
a bridging ligand between the two simultaneously occupied sites, but it has also been observed 
bound only to site C. By substituting this residue with Ala, a non-coordinating residue, the 
intention was to test the importance of a ligand that connects site B and C.  
4.3 E44Q variant of PmFTN 
Having established that the substitution of the three Cys residues of PmFTN does not 
significantly affect the iron-storage properties of the protein, a further mutation was introduced, 
resulting in the substitution of Glu44 with glutamine (E44Q). For the sake of brevity, that the 
substitution is in a Cys-free background won’t be referred to again.  
To test the capacity of the E44Q variant to store iron, sequential additions of 400 Fe(II) were 
made, see Figure 4.4A. This shows that significant precipitation occurs after 1600 Fe(II) ions 
were added, and after 2800 Fe(II) ions the protein was completely precipitated.  Figure 4.4B 
shows a plot of the initial rate of Fe(II) oxidation as a function of Fe(II) ions added per E44Q 
PmFTN.  It shows a maximum initial rate at around 1200 Fe(II) ions.  At 2400 Fe(II) ions added, 
the rate of oxidation increased again, with the lowest initial rate of oxidation at 400 Fe(II) ions 
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and 2800 Fe(II) ions. However, above 1600 irons per protein, it is clear that very little additional 
iron is actually stored in the protein.  
 
 
Figure 4.4.  Iron mineralisation in E44Q PmFTN. (A) Absorbance changes at 340 nm 
showing Fe(II) oxidation in the presence of 0. 5 µM PmFTN in 0.1 MES pH 6.5.  
Numbers indicate total Fe(II) ion additions (sequentially added 400 Fe(II) ions per 
PmFTN) at 25 °C and pathlength 1 cm. (B) Plot of rate of Fe(II) oxidation, catalysed by 
0.5 µM PmFTN in 0.1 MES pH 6.5, as a function of Fe(II) ions added per PmFTN.  
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4.3.1 Fe(II) oxidation kinetics at the ferroxidase centre 
Figure 4.5A shows the absorption changes at 340 nm following the mixing of 1.2 µM apo-E44Q 
PmFTN variant, in 0.1 M MES buffer at pH 6.5, with various amounts of ferrous iron as function 
of time. Similar to wild-type proteins, it shows a very rapid oxidation phase, the oxidation being 
completed within 0.5 seconds.  A plot of ΔA340 nm as a function of Fe(II), Figure 4.5B, reveals 
quite different behaviour to that of the wild-type protein, however.  Absorption changes are small 
up to a level of ~ 30 Fe(II) per protein, after which they significantly increase, levelling off when 
all 24 subunits have bound ~2 equivalents of Fe(II), consistent with binding and oxidation of two 
Fe(II) ions per ferroxidase centre. This initial shallow slope is indicative of negative 
cooperatively with binding of one Fe(II) at each ferroxidase centre favoured over double 
occupancy. If two Fe(II) ions are required for oxidation to occur, this would account for why 
ΔA340 nm increases significantly above a level of ~1 Fe(II) per subunit.  
Figure 4.5C shows the fits of the E44Q variant data to either single or double exponential 
functions (as needed), providing an observed (pseudo-first order) rate constant, k. A plot of k,as a 
function of Fe(II) concentration, Figure 4.5D, reveals a linear relationship, demonstrating a first 
order dependence of the rate of oxidation on the concentration of Fe(II), as observed for the 
wild-type protein, giving an apparent second order rate constant, k, of 3.13(+0.0027) x 105 M-1 s-1.  
This is slightly higher than the wild-type protein rate constant.  In terms of rate, the ferroxidase 
centre reaction in the E44Q variant is not significantly affected.  
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Figure 4.5. Kinetic analyses of Fe(II) oxidation catalysed by E44Q PmFTN (A) Fe(II) 
was added to final concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80 and 100 µM to 
PmFTN (1.2 µM) in MES buffer (0.1 M, pH 6.5, 25 °C) using a stopped-flow 
instrument. (B) Plot of observed (pseudo-first order) rate constants, obtained from 
fitting the data in A, as a function of Fe(II) concentration.  A linear fit of the data is 
drawn in. (C). Final absorbance change after 0.5 seconds of iron oxidation at various 
ratios of Fe(II)/PmFTN subunit concentration. The three clear phases are highlighted, 
intersecting at ~30 and ~60 Fe(II) per protein, represented by the dotted line. (D). 
Fitting of PmFTN-catalysed Fe(II) oxidation data.  Each of the A340 nm traces 
corresponding to additions of 8 – 81 Fe(II) ions per PmFTN were fitted to a single and 
double exponential function. The solid line fits are shown along with the data from part 
A. 
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4.3.2 Regeneration of rapid oxidation in PmFTN 
Variant E44Q was also examined to determine whether the extremely rapid oxidation of Fe(II) 
observed upon addition of 48 Fe(II) per PmFTN can be regenerated. PmFTN was loaded with 48 
Fe(II) per 24mer and then subsequently incubated for 30 minutes or 20 hours.  Then, a further 
aliquot of Fe(II) (either 41 or 83 Fe(II) per protein) was added and changes in A340 nm were 
measured. Figure 4.6A shows changes A340 nm over 100 seconds after incubation for 30 
minutes. Figure 4.6B shows A340nm over 1000 seconds with similar conditions. Clearly, rapid 
oxidation is not observed. The incubation over 20 hours showed similar behaviour to the 20 
minutes incubation (not shown). The data are distinct from that of wild-type in that oxidation is 
complete within ~ 300 seconds for the addition of 40 Fe(II) per protein and ~600 seconds for 80 
Fe(II) per protein.  
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Figure 4.6. Kinetic analyses of Fe(II) oxidation catalysed by E44Q PmFTN. (A) and (B) 
stopped-flow measurements of absorbance changes at 340 nm following the addition of 
41 or 83 Fe(II) ions per protein to a sample of PmFTN previously treated with 50 Fe(II) 
per protein under aerobic conditions. The incubation time between Fe(II) additions was 
30 min.  1.2 µM PmFTN was in 0.1 M MES pH 6.5. 
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4.4 E44H variant of PmFTN 
Another Glu44 variant, E44H, was also investigated. In this case, the substitution was introduced 
to the wild-type protein and the variant protein was alkylated prior to study.   
4.4.1 Fe(II) oxidation kinetics at the ferroxidase centre 
Figure 4.7A shows the absorption changes at 340 nm following the mixing of 1.2 µM apo-E44H 
PmFTN variant, in 0.1 M MES buffer at pH 6.5, with various amounts of ferrous iron as function 
of time. Similar to alkylated-wild type it showed a very rapid oxidation of ferrous ion, the 
oxidation being completed within 0.5 seconds.  As with E44Q, a plot of ΔA340nm (Figure 4.7B) 
versus Fe(II) consists of an initial low amplitude phase up to ~24 Fe(II) per protein (1 Fe(II) per 
subunit)  followed by a much larger increase in ΔA340nm up to ~56 Fe(II) per protein. As for 
E44Q, this indicates the presence of negative cooperativity. 
Each Fe(II) oxidation trace was fitted to a either a single or double exponential function, 
providing an observed (pseudo-first order) rate constant, k, Figure 4.7C.  A plot of ko as a 
function of Fe(II) concentration, Figure 4.7D, revealed, as for wild-type PmFTN, a linear 
relationship, demonstrating a first order dependence of the rate of oxidation on the concentration 
of Fe(II). The slope of the line provides an apparent second order rate constant, k, of 1.02(+0.74) 
x 105 M-1 s-1. This value is lower than that of the wild-type protein indicating that the lack of Glu 
at position 44 has some effect on the rate of ferroxidase reaction.  
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Figure 4.7. Kinetic analyses of Fe(II) oxidation catalysed by E44H PmFTN (A) Fe(II) 
was added to final concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80 and 100 µM to 
PmFTN (1.2 µM) in MES buffer (0.1 M, pH 6.5, 25 °C) using a stopped-flow 
instrument. (B) Plot of observed (pseudo-first order) rate constants, obtained from 
fitting the data in A, as a function of Fe(II) concentration.  A linear fit of the data is 
drawn in. (C). Final absorbance change after 0.5 seconds of iron oxidation at various 
ratios of Fe(II)/PmFTN subunit concentration. The three clear phases are highlighted, 
intersecting at ~24 and ~56 Fe(II) per protein, represented by the dotted line. (D). 
Fitting of PmFTN-catalysed Fe(II) oxidation data.  Each of the A340 nm traces 
corresponding to additions of 8 – 81 Fe(II) ions per PmFTN were fitted to a single and 
double exponential function. The solid line fits are shown along with the data from part 
A. 
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4.4.2 Regeneration of rapid oxidation in PmFTN 
E44H PmFTN was also examined to determine whether the extremely rapid oxidation of Fe(II) 
observed upon addition of 48 Fe(II) per PmFTN can be regenerated. PmFTN was loaded with 48 
Fe(II) per 24mer and then subsequently incubated for 30 minutes or 20 hours.  Then, a further 
aliquot of Fe(II) (either 41 or 83 Fe(II) per protein) was added and changes in A340 nm were 
measured. Figure 4.8A shows changes in A340 nm over 100 seconds after incubation for 30 
minutes. As for the other proteins in this study, rapid oxidation is not seen.  Furthermore, 
oxidation is not complete even over 1000 s as shown in Figure 4.8B. The incubation over 20 
hours showed similar behaviour to the 20 minutes incubation. The data are very similar to that of 
wild-type PmFTN and therefore distinct from E44Q (in the Cys-free background).  
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Figure 4.8. Kinetic analyses of Fe(II) oxidation catalysed by E44H PmFTN. (A) and (B) 
stopped-flow measurements of absorbance changes at 340 nm following the addition of 
40 or 80 Fe(II) ions per protein to a sample of PmFTN previously treated with 50 Fe(II) 
per protein under aerobic conditions. The incubation time between Fe(II) additions was 
30 min.  1.2 µM PmFTN was in 0.1 M MES pH 6.5. 
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4.5 E130A variant of PmFTN 
The final site directed variant that was studied was E130A which was generated in a wild-type 
background and alkylated.  
4.5.1 Fe(II) oxidation kinetics at the ferroxidase centre 
Figure 4.9A shows the absorption changes following the mixing of 1.2 µM apo-E130A PmFTN, 
in 0.1 M MES buffer at pH 6.5, with various amounts of ferrous iron as function of time. Similar 
to wild-type protein it shows a very fast rapid oxidation of ferrous ion, the oxidation being 
completed within 0.5 seconds.  As in the Glu44 variants, a plot of ΔA 340 nm  as a function of 
Fe(II)/protein consists of three phases: an initial shallow phase breaking at ~1 Fe(II) per subunit, 
a steep second phase saturating at ~2 Fe(II) per subunit, and a third shallow phase (Figure 4.9B).  
As for both Glu44 variants, E130A exhibits negative cooperativity in terms of Fe(II) binding.  
Figure 4.9C shows that each trace for E130A fitted well to a single exponential function, 
providing an observed (pseudo-first order) rate constant, k. A plot of k as a function of Fe(II) 
concentration, gave a straight line, again demonstrating a first order dependence of the rate of 
oxidation on the concentration of Fe(II). The slope of the line in Figure 4.9D provides an 
apparent second order rate constant, k, of 1.75(+0.17) x 105 M-1 s-1, which is somewhat lower 
than that of the wild-type protein.  
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Figure 4. 9. Kinetic analyses of Fe(II) oxidation catalysed by E130A PmFTN (A) Fe(II) 
was added to final concentrations of 0, 10, 20, 30, 40, 50, 60, 70, 80 and 100 µM to 
PmFTN protein (1.2 µM) in MES buffer (0.1 M, pH 6.5, 25 °C) using a stopped-flow 
instrument. (B) Plot of observed (pseudo-first order) rate constants, obtained from fitting 
the data in A, as a function of Fe(II) concentration.  A linear fit of the data is drawn in. 
(C). Final absorbance change after 0.5 seconds of iron oxidation at various ratios of 
Fe(II)/PmFTN subunit concentration. The three clear phases are highlighted, intersecting 
at ~24 and ~52 Fe(II) per protein, represented by the dotted line. (D). Fitting of PmFTN-
catalysed Fe(II) oxidation data.  Each of the A340 nm traces corresponding to additions 
of 8 – 81 Fe(II) ions per PmFTN were fitted to a single exponential function. The solid 
line fits are shown along with the data from part A. 
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4.5.2 Regeneration of rapid oxidation in PmFTN 
The ability of E130A PmFTN to regenerate its rapid oxidation phase was investigated.  E130A 
PmFTN was loaded with 48 Fe(II) per 24mer and then subsequently incubated for 30 minutes or 
20 hours.  Then, a further aliquot of Fe(II) (either 41 or 83 Fe(II) per protein) was added and 
changes in A340 nm were measured. Figure 4.10A shows changes in A340 nm over 100 seconds 
after incubation for 30 minutes, and Figure 4.10B shows over 1000 seconds . As for all other 
PmFTN in proteins studied here, rapid oxidation is not seen.  However, oxidation was complete 
for addition of 40 and 80 Fe(II) per protein within 200 seconds, much more rapidly than in a 
wild-type PmFTN or the Glu44 variants.  The incubation over 20 hours showed similar 
behaviour to the 20 minutes incubation (not shown).  
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Figure 4.10. Kinetic analyses of Fe(II) oxidation catalysed by E130H PmFTN. (A) and 
(B) stopped-flow measurements of absorbance changes at 340 nm following the addition 
of 41 or 83 Fe(II) ions per protein to a sample of PmFTN previously treated with 50 
Fe(II) per protein under aerobic conditions. The incubation time between Fe(II) 
additions was 30 min.  1.2 µM PmFTN was in 0.1 M MES pH 6.5. 
 
 
 
 
0	  
0.01	  
0.02	  
0.03	  
0.04	  
0.05	  
0.06	  
0.07	  
0.08	  
0	   10	   20	   30	   40	   50	   60	   70	   80	   90	   100	  
ΔA
34
0	  
nm
	  
Time	  (S)	  
	  	  Fe(II)/24mer	  
41	  
83	  
A	  
0	  
0.01	  
0.02	  
0.03	  
0.04	  
0.05	  
0.06	  
0.07	  
0.08	  
0	   100	   200	   300	   400	   500	   600	   700	   800	   900	   1000	  
ΔA
34
0	  
nm
	  
Time	  (S)	  
	  	  	  	  	  Fe(II)/24mer	  
41	  
83	  
B	  
	   89	  
4.6 Iron core formation kinetics in PmFTN 
Given the difference observed in the kinetics of Fe(II) oxidation in regeneration experiments, the 
ability of the E130A to store iron was investigated further and compared directly with the other 
variants. Iron core formation kinetics following addition of 400 of Fe(II) ions per apo-PmFTN 
(wild-type and variant proteins) were followed by monitoring absorbance changes at 340 nm for 
1000 seconds, as  shown in Figure 4.11.  Mineralisation involves the binding and oxidation of 
Fe(II) but the mechanism for this process in PmFTN is not known. The data for E44Q is similar 
to that for wild-type PmFTN, while mineralisation in E44H PmFTN is significantly slower.  
Remarkably, mineralisation in the variant E130A occurs much more rapidly and is complete 
within 400 seconds (compared to 1800 seconds for the wild-type protein).    
 
Figure 4.11. Absorbance changes at 340 nm showing Fe(II) oxidation in the presence of 
0.5 µM wild-type and various PmFTN in 0.1 MES pH 6.5. 400 Fe(II) ions per PmFTN 
were added at 25 °C and pathlength 1 cm. 
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4.7 Discussion  
Third iron site is generally not associated with ferritin ferroxidase sites.  The site C has been 
observed in some non-heme ferritins from bacteria and archaea: E. coli (EcFtnA) (33, 55), 
Pyrococcus furiosus (PfFtn) (34), and Archaeoglobus fulgidus (AfFtn) (68).  However, these 
sites vary from that of PmFTN in terms of the number and origin of coordinating glutamate 
residue.  One of these residues is Glu130, which is seen to bridge the iron atom of site B and C 
(Figure 4.12) and is conserved in prokaryotic ferritins. In EcFtnA Glu130 is proposed to adjust 
its position so it can bind iron ions in sites B and C as well as gating the passage of the iron 
through these sites (69). Similarly, in PmFTN Glu44 and Glu130 may provide similar function of 
gating the passage of iron from site B to site C.  
 
 
 
 
 
 
 
 
 
 
  
 
Figure 4.12. The substituted residues Glu44 and Glu130, shown in red, exhibits 
coordination at site C. Iron Glu130 is also observed coordinating to site B. Water 
molecule show in blue sphere. 
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PmFTN contains three Cys residues, which presented a challenge during crystallization; 
therefore, they were alkylated or removed in order to improve the stability of the protein.  Here, 
the alternative strategy of substitution with alanines was attempted. Our results suggest that 
substitution of three Cys residues of PmFTN (Figure 4.2) resulted in a protein with properties 
similar to those of the alkylated (and non-alkylated) wild-type protein, as seen in Chapter 3.  This 
suggests the three Cys residues do not play an important role in Fe(II) oxidation and iron uptake.  
The data suggest that variants E44Q (in Cys-free background), E44H (alkylated) and H130A 
(alkylated) all exhibited raid phase 2 oxidation of Fe(II) at the ferroxidase centre with a rate only 
slightly lower than that of the wild-type protein.  However, the shape of the ΔA340 nm versus Fe(II) 
plot was different, in each case, to that of the wild-type protein.  Rather than a linear increase 
toward a point of saturation corresponding to 2 Fe(II) ions per subunit, distinct phases below and 
above a level of 1 Fe(II) per subunit were observed.  At low Fe(II) levels (up to 1 Fe(II) per 
subunit) very low intensity increases in ΔA340 nm were observed, indicating that very little Fe(II) 
oxidation had occurred.  Above a level of 1 Fe(II) per subunit, much larger absorbance changes 
were detected, indicating that the majority of Fe(II) oxidation occurred here.  This is interpreted 
in terms of negative cooperativity of Fe(II) binding to the ferroxidase centre variants.  Thus, in 
these variants, Fe(II) binds to the apo-ferroxidase centre in preference to a centre that already 
contains an Fe(II) ion.  Because Fe(II) oxidation only occurs when the centre contains two Fe(II) 
ions, significant oxidation only occurs when more than 24 Fe(II) ions are added to the protein.  It 
is likely that the affinity of Fe(II) for site B is affected in the variants, since the substitution are 
close to site B.  In the case of E130A, the residue actually coordinates Fe(II) at site B. However, 
it is noticeable that the two Glu44 variants exhibit cooperativity to a greater extent. As for the 
wild-type protein, none of the variants exhibited a regeneration of the rapid ferroxidase reaction. 
E44Q and E130A exhibited some differences from wild-type protein in that oxidation of a 
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second aliquot of Fe(II) was complete much sooner than for the wild-type protein.  This was 
much more apparent in E130A than in E44Q.  
Addition of 400 Fe(II) per E130A PmFTN revealed a very significantly enhanced rate of 
mineralisation compared to wild-type and E44Q and E44H proteins (Figure 4.11). This is an 
unusual observation in that mutations do not normally significantly enhance activity. Mutation of 
site C in EcFtnA leads to a small reduction in the oxidation rate, and also an increase of iron 
movement to the iron core.  These observation with EcFtnA led to the suggestion that the 
presence of site C offers advantages, for example, an increase of iron oxidation stoichiometry 
from 2 Fe(II)/O2 in HuHF to 3–4 in EcFtnA perhaps avoids the production of reactive oxygen 
species.  Also iron is retained longer at the ferroxidase centre/site C in the protein shell and is 
perhaps more easily accessible to iron-requiring anabolic process in the cell (55).  Similarly, in 
E130A iron mobility may be affected.   
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Chapter 5: Mechanistic study of iron release from Bacterioferritin 
 
5.1 Purifications in BFR  
 
The BFR protein, expressed in E. coli pALN1 cells, was purified as described in chapter 2. 
SDS−PAGE analysis was used to monitor purity during the preparation, see the gels shown in 
Figure 5.1A and 5.1B. The band corresponds to an approximate Mw of 18.6 kDa, in agreement 
with the Mw calculated from the amino acid sequence of a BFR subunit (18,553 Da). Note that 
anion exchange was employed to remove DNA contamination of the protein.  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.1. SDS-PAGE analysis of wild-type BFR purification.  Lane 1, post sonication 
step (after centrifugation): lane 2, after heat shock step (after centrifugation); lane 3, 
ammonium sulphate step (55 percent cut, before centrifugation); lane 4, dialysis step 
(before centrifugation); lane 5, after gel filtration column (outer pool); lane 6, after gel 
filtration column (outer pool); lane 7 and 8, after gel filtration column (inner pool); lane 
9, after gel filtration column (inner pool). (B) SDS-PAGE analysis of BFR following 
anionic exchange chromatography. Lane 1, 2 and 3, Wt BFR (inner pool). 
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5.2 Heme loading of E. coli BFR via a heat-treatment method  
 
5.2.1 The addition of exogenous heme to wild-type BFR 
 
In order to examine the role of heme in iron release from BFR it is necessary to have access to as 
wide a range of heme loadings as possible.  However, the heme-binding site of BFR is not 
accessible from the outside of the protein and so, previously, heme incorporation needed to occur 
during protein assembly. Addition of exogenous heme to BFR in a high salt buffer (1 M NaCl 
0.1 MES pH 6.5) at 25 °C result in changes in the UV-visible absorbance spectrum that are not 
consistent with specific binding of heme at its native site (Figure 5.2).  In comparison, addition 
of heme to an identical sample of BFR followed by heating to 80 °C for 15 minutes resulted in 
very different changes in the UV-visible absorbance spectrum, without any significant 
precipitation of the protein. Following the addition of heme, the sample was cooled to room 
temperature and free and non-specifically bound heme was removed by passage of the sample 
through a PD-10 desalting column.  This resulted in BFR containing an increased level of heme 
(Figure 5.3).  The spectroscopic characteristics of the bound heme, in particular the Soret 
maximum at 418 nm and the absorbance at ~739 nm, which is indicative of bis-methionine 
ligation of heme, are identical to those of the naturally heme loaded protein (38).   
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Figure 5.2.  Addition of exogenous heme to BFR at 25 °C. UV-visible spectra 0.5 µM 
BFR in 0.1 M MES pH 6.5 and 1 M NaCl before heme addition (solid line) and after 
addition of heme (dashed line).Pathlength 1 cm. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.3. Addition of exogenous heme to BFR in a high salt buffer at 80 °C. spectra 
of 0.5 µM BFR in 0.1 M MES pH 6.5 and 1 M NaCl before heme addition (–), after 
addition of heme (--), after addition of heme and heating to 80 °C (---), and (–) passing 
through a desalting column. Inset is an expanded plot of absorbance showing the region 
of the spectrum in which a charge transfer band characteristic of bis-Methionine axial 
coordination occurs. Pathlength 1 cm. 
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Furthermore, addition of variable amounts of heme followed by the heat treatment yielded 
protein samples with various amounts of heme.  Figure 5.4 shows BFR with 5, 6, 7, and 11 
hemes.  Note that overexpressed recombinant BFR usually contains very low levels of heme 
(approximately one hemes per 24mer).  Thus, through this method, nearly fully heme loaded 
BFR was obtained. 
 
 
Figure 5.4. UV-visible spectra of heme-binding to BFR. Spectra of 0.5 µM BFR in 0.1 
M MES pH 6.5 and 1 M NaCl with varying levels of heme content after heme addition, 
heating to 80 °C and passage through a desalting column.  BFR containing 5 (–), 6 (–), 
7 (--), and 11 (--) hemes per protein. Pathlength 1 cm. 
 
5.2.2 The addition of exogenous heme to heme-free (M52H) variant of BFR 
To provide further evidence that the heme bound by wild-type BFR following heat treatment is 
bound at the native Met52/Met52 coordinated site, a site directed variant of BFR, M52H was 
employed. Previous studies of M52H BFR showed that the protein is isolated in a heme-free 
state, regardless of the fact that histidine is a typical coaxial heme ligand, found in many other 
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hemoproteins. This points to lack of flexibility at the heme site such that His is not positioned 
sufficiently well to coordinate heme above and below the plane, and the importance of Met52 in 
mediating the tight fit of the heme at its binding site in BFR (39).   
Addition of heme with similar treatment as wild-type BFR, as described above, prompted 
approximately 25-35% of the variant protein to precipitate when heated at 80 ◦ C. Heating M52H 
in the absence of heme did not unfavorably affect the protein stability.  Addition of heme without 
heating also did not lead to precipitation.  Hence, the combination of heating at 80 ◦ C and the 
presence of heme caused instability and loss of the protein from solution.  To overcome this 
problem, M52H BFR containing 12 equivalents of heme per BFR (24mer) was heated to 65 ◦ C. 
This resulted in  <10% precipitation of the variant protein.  The removal of free and 
adventitiously bound heme was achieved by passage of the sample through a PD-10 desalting 
column.  This resulted in the absorbance spectrum shown in Figure 5.5. The spectrum shows that 
a small amount of heme is bound to the protein.  On closer inspection, see inset of Figure 5.5, the 
heme Soret band is not located at 418 nm, but rather at 405 nm.  This is similar to the spectrum 
of met myoglobin and heme oxygenase (70, 71).  This suggests that the ferric heme iron is bound 
by a single histidine residue.  If is assumed that this heme has the same heme molar absorptivity 
as that reported for heme oxygenase for its Soret absorbance at 405 nm (1.4 x 105  M-1 cm-1) (72), 
about 0.3-0.4 mol of heme is bound to the M52H (24mer). Thus, the M52H variant is incapable 
of binding significant amounts of heme through the described post-purification method.   
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Figure 5.5. UV-visible absorbance spectrua of M52H before and after addition of 
heme. 0.5 µM M52H in 0.1 M MES pH 6.5 and 1 M NaCl before (–) and after (–) heme 
addition. Note that elution from a PD-10 desalting column results in a 1.5 x dilution of 
the protein.  Insets are expanded plots of the 350-450 and 650-800 nm regions. 
Pathlength 1 cm. 
 
 
To further confirm that the inability of M52H BFR to bind significant amounts of heme was not 
a result of the lower temperature employed during the procedure, wild-type BFR was treated 
with 12 mol equivalents of heme at 65 ◦ C and eluted through a PD-10 column. In comparison to 
treatment at 80 ◦ C, this method was not as efficient in promoting heme-binding, see Figure 5.6.  
The absorbance spectrum was identical with that following treatment at 80 ◦ C, with the Soret 
band at 418 and absorbance at ~739 nm, which is indictive of bis-methionine ligation of heme.  
However, binding was limited to about 8 hemes per BFR (24mer).  Furthermore, a low intensity 
band at approximately 650 nm was observed that was not apparent previously. This indicates the 
presence of some high-spin ferric-heme possibly due to heterogeneity of heme-binding at the 
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native binding site, with coordination of one Met52 instead of two.  Overall, the data indicate 
that wild-type BFR, even at lower temperature, binds heme at the natural bis-methionine 
coordination site (51).   
 
 
Figure 5.6. UV-visible absorbance spectra of wild-type BFR before (–) and after (–) 
heme additon at 65 °C. BFR (0.5 µM) was in 0.1 M MES pH 6.5 and 1 M NaCl before 
heme addition.  The sample was diluted during desalting to remove unbound or weakly 
bound heme.  Inset is an expanded plot of absorbance at ~739 nm which is indictive of 
bis-methionine ligation of heme. Pathlength 1 cm. 
 
In order to further characterize the low amount of heme bound to M52H, a more concentrated 
sample was needed. However, an effort to concentrate samples of M52H BFR resulted in loss of 
heme.  This suggest that the heme is not stably coordinated to this variant of BFR, which is 
consistent with previous studies of expression in E. coli, which led to a protein without heme 
bound. Also, an attempt was made to reduce heme-M52H BFR using excess sodium dithionite.  
Wild-type BFR loaded with 9 hemes per protein was also treated with excess dithionite. The 
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absorption peaks at 418, 525, and 560 nm associated with the Soret, β, and α band of the 
oxidised heme moiety, observed in 9 heme loaded BFR, were absent from the spectrum of M52H 
BFR (Figure 5.7 and Figure 5.8). Instead, a reduction in heme intensity was observed, with a 
minor increase in intensity in the 700 nm region.   
 
Figure 5.7. U.V- visible spectra of E. coli M52H BFR as isolated (solid line) and 
following treatment with excess sodium dithionite (dotted line). 2.8 µM M52H BFR in 
0.1 M MES pH 6.5 and 1 M NaCl. Inset is an expanded plot of the 650-800 nm region. 
Pathlength 1 cm.  
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Figure 5.8.  U.V-visible spectra of heme-loaded E. coli wild-type BFR (solid line) and 
following treatment with excess sodium dithionite (dotted line). 2.5 µM BFR in 0.1 M 
MES pH 6.5 and 1 M NaCl. Insets are expanded plots of the 500-600 and 650-800 nm 
regions. Pathlength 1 cm.  
 
 
5.3  The effect of heme on mineralisation and iron release from E. coli BFR  
 
5.3.1  Effect of heme on E. coli BFR iron core formation  
The effect of heme bound to BFR on Phase 3 of mineralisation was studied by monitoring 
absorption changes at 340 nm after three sequential additions of 200 µM Fe(II) to 0.5 µM wild-
type BFR in 0.1 M MES buffer at pH 6.5, and  at 25 °C. Similar procedures were performed (0.5 
µM protein in 0.1 M MES buffer at pH 6.5, and  at 25 °C) using heme loaded BFR (added via the 
method described above) and heme-free M52H BFR. The absorption changes with the first 
addition of iron resulted in an initial increase in absorbance.  This instant jump (referred to as 
phase 2) is due to two Fe(II) ions becoming oxidised to Fe(III) ions at the dinuclear ferroxidase 
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centre located within each subunit. After the completion of Phase 2, if sufficient Fe(II) is present, 
iron is slowly oxidised (phase 3) leading to iron core formation. This is observed only under 
conditions where more Fe(II) is added than is required for full occupancy of the dinuclear sites. 
Figure 5.9 shows absorbance changes at 340 nm following sequential additions of 400 Fe(II) per 
protein. There is a clear difference in behaviour between the as isolated protein, which contains ~ 
1 heme per 24mer, and the artificially heme loaded protein (containing 11 hemes per 24mer). For 
the first addition of iron, BFR with 11 hemes exhibited a lower rate of nucleation and initial iron 
core formation and essentially a sigmoidal shape. For the second and third additions of iron, the 
BFR with 11 hemes displayed significantly higher mineralisation rates, see Figure 5.10. 
 
Figure 5.9. Iron uptake into E. coli BFR. 200 µM Fe2+ was added to 0.5 µM BFR as 
isolated BFR (–), and BFR with 11 hemes (–) in MES buffer 0.1M, pH 6.5, 25 °C. 
Pathlength 1 cm. 
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Figure 5.10. Phase three Fe(II) oxidation rates for isolated BFR containing 1 heme and 
heme loaded BFR with11 hemes. The first initial rates of iron oxidation (400), second 
initial rates of iron oxidation (800 iron), third oxidation rate with addition of iron to 
BFR 11 hemes are shown (1200 iron). See Figure 5.9 for experimental details.  
 
 
Similar experiment were conducted with BFR loaded with 6 hemes, see Figure 5.11. Again, 
behaviour was somewhat different from that of as isolated BFR.   
 
 
Figure 5.11. Iron uptake into E. coli BFR. 200 µM Fe2+ was added to 0.5 µM BFR as 
isolated BFR (–), and BFR with 6 hemes (–) in MES buffer 0.1 M, pH 6.5, 25 °C.  
Pathlength 1 cm.  
 
0	  
0.1	  
0.2	  
0.3	  
0.4	  
0.5	  
0.6	  
0.7	  
0.8	  
0	   20	   40	   60	   80	   100	   120	  
ΔA
34
0	  
nm
	  
Time	  (min)	  
1200	  	  
800	  	  
400	  	  
	   104	  
 
 
 
 
 
 
 
Figure 5.12. Phase three oxidation in BFR with isolated BFR (1 heme) and BFR with 
(6 heme). The first initial rates of iron oxidation (400 iron), second initial rates of iron 
oxidation (800 iron), third oxidation rate with addition of iron to BFR 6 heme are 
shown (1200). See Figure 5.11 for experimental details. 
 
 
5.3.2  Effect of heme on iron release from E. coli BFR 
 
 
BFRs are distinct from other ferritin-like proteins in that they contain heme.  The BFR 24mer 
possesses 12 heme-binding sites that are located at intersubunit sites coordinated by Met52 of 
each subunit, generating unusual bis-methionine axial ligation.  Previous studies demonstrated 
that heme does not play a crucial a role in the early stages of iron core formation (39). Recent 
studies of E. coli BFR with higher heme bound revealed a decrease in the rate of iron oxidation 
at the ferroxidase sites (phase 2) an but increase in the rate of iron core formation (phase 3), 
consistent with the date in Figure 5.9 (51).  However, it was demonstrated recently that heme 
also plays an important role in iron release (27), although, that study was confined to BFR 
containing zero, one and five hemes per 24mer (27).  A full investigation of the functional role of 
heme in E. coli BFR has been hampered by the difficulty in preparing BFR samples containing 
high heme levels. Overexpression of recombinant BFR usually yields very low levels of heme, 
and exogenous heme cannot be added to reconstitute the unoccupied heme-binding sites.  Heme 
levels were increased to ~5 per protein by induction of protein production with very low 
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concentration of the inducer, IPTG. In order to overcome this difficulty, we utilized the 
procedure that allows the reconstitution of E. coli BFR sample with higher amounts of bound 
heme. We wished to evaluate, using BFR samples containing a range of heme loadings, whether 
higher heme levels are important for iron release and the influence of varying heme on the 
kinetics of iron release. Therefore, these investigations were directed at studying the mobilization 
of core iron from as isolated wild-type BFR, BFR with various heme added, and heme free 
M52H BFR. A commonly used chelator-based assay was initially employed. This assay is used 
was initially employed with the assumption that the chelator does not interfere with the release of 
iron reaction, see scheme 1.  
 
 
 
 
 Scheme I. 
 
In the assay, the reaction was initiated by addition of the reductant system, sodium 
dithionite/FMN, to a cuvette containing a solution of ferrozine (1 mM) and BFR mineralized 
with 1200 iron ions. The process was monitored by following the absorbance change at 562 
nm the due to time-dependent formation of [Fe(II)(ferrozine)
3
]
4-
.  In the absence of reductant an 
rapid increase at 562 nm was not observed, due to lack of free Fe2+ (27).  The addition of sodium 
dithionite 100 µM, 100 µM FMN to BFR containing ~1200 Fe3+/protein and 6 hemes resulted in 
an increase of absorption overtime, indicating that electrons were supplied to the mineral core to 
reduce iron from Fe3+ to Fe2+ leading to formation of the Fe2+-chelator complex. The kinetic 
profile of iron release at pH 6 and pH 7 demonstrated that, although some differences were 
observed, there was no great variation in iron release kinetics upon varying pH (Figure 5.13).  
This behaviour is similar to that previously reported for BFR; some variation was seen when 
 
BFR-Fe3+ + e-                      BFR-Fe2+ 
BFR-Fe2+                              BFR + Fe2+ 
Fe2+ + chelator                     Fe2+ - chelator  
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comparing ferrozine and bipyridyl at the two pH values but it was concluded that variation is due 
to the effect of chelator and not to pH (27).  The data were relatively similar with a rapid phase 
occurring in less than five minutes, and a slower phase that occurs after 5 minutes. The data 
showed wild-type BFR with 1 heme had a slightly lower rate of iron release than BFR with 6 
hemes.  Data was fitted well to a double exponential function, with the majority of the amplitude 
associated with the first phase. For pH 7, fits provided rate constants of 1.82 (+0.006) min-1 and 
1.876 (+0.007) min-1 for as isolated BFR and 6 heme BFR, respectively. For pH 6, rate constants 
of 1.44 (+0.01) min-1 and 1.46 (+0.02) min-1 were obtained for as isolated BFR and 6 heme BFR, 
respectively.  The extent of iron release was also calculated using [Fe(II)(ferrozine)3]4− complex 
using (ϵ562 nm = 28,000 M−1 cm−1) and absorbance at the end of each release reaction.  The extent 
of iron release at pH 7, 52.0% and 44.1% were obtained for as isolated BFR and 6 heme BFR, 
respectively. For pH 6, 45.2% and 43.1% value were acquired for as isolated BFR and 6 heme 
BFR.  Thus, the rate constants for iron release are not significantly different.  The extent of iron 
release was reduced for the 6-heme containing sample.  
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Figure 5.13. The influence of heme on iron release from E. coli BFR, utilizing 
dithionite/FMN as reductant and ferrozine as chelator.  Time-dependent increases of 
A562nm following the addition of 100 µM dithionite and 100 µM FMN to either 6 heme 
loaded BFR (blue line) or as isolated wild-type containing 1 heme BFR (red line) in the 
presence of 1 mM Ferrozine. Both BFRs were loaded with 1200 iron ions (0.05 µM 
BFR) in MBS. The release reaction was carried out at 25 °C. (A) pH 7 and (B) pH 6. 
Pathlength 1 cm. 
 
The data suggest there are two phases in iron release, a very rapid phase and a slower phase that 
increased overtime in the presence of excess reductant. Furthermore, additions of sodium 
dithionite (200 µM) to 0.05 µM BFR loaded with 11 hemes and as isolated wild-type BFR in 
MBS buffer in the presence of the chelator Ferrozine (1 mM) at pH 7, also resulted in a much 
reduced extent of iron release for the 11 hemes sample compared to as isolated wild-type BFR 
that contains 1 heme (Figure 5.14). The data demonstrated lower iron release in the presence of 
higher heme levels. The data was fitted well to a double exponential function, with the majority 
of the amplitude associated with the first phase. This gave rate constants of 0.785 (+0.005) min-1, 
and 1.045 (+0.008) min-1 for as isolated BFR and 11 hemes BFR, respectively.  The extent of 
iron release was also calculated, 67.9 % and 33.7% value were obtained for as isolated BFR and 
11 hemes BFR, respectively.  Thus, an increase in heme content resulted in a small increase in 
the rate of iron release, but a decrease in the extent of iron release.  
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Figure 5.14. The influence of heme on iron release from E. coli BFR utilizing 
dithionite as a reductant and ferrozine as a chelator.  Time-dependent increases of 
ΔA562nm following the addition of 200 µM dithionite, to either 11 heme loaded 
BFR(dashed lines) or isolated wild-type containing 1 heme BFR (solid line).   Both 
BFRs were loaded with 1200 iron ions (0.05 µM BFR) in MBS, 1 mM Ferrozine as a 
chelator and conducted pH 7 and at 25 °C. Pathlength 1 cm. 
 
The data presented here indicate quite different behaviour compared to that previously reported 
(27).  To check that this was not due to a problem with how the experiments were being 
performed some additional checks were made.  Similar experiments were carried out with heme-
free M52H BFR and as isolated wild-type BFR using the FMN/dithionite-chelator assay in an 
anaerobic environment at pH 7 and pH 6. Figure 5.15 shows a plot of absorbance change at 562 
nm as a function of time following the addition of sodium dithionite 100 µM, 75 µM FMN to 
BFR proteins containing ~1200 Fe3+/protein in MBS buffer with Ferrozine (1 mM). The data 
demonstrated iron release was pH dependent and heme-free M52H BFR exhibited a lower rate 
and extent of iron release compared to wild-type BFR. Data was fitted well to a double 
exponential function, with the majority of the amplitude associated with the first phase.  For pH 
7, it provided rate constant of 3.83 (+0.004) min-1, and 2.94 (+0.005) min-1 for as isolated BFR 
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and heme-free M52H BFR, respectively. For pH 6, it provided rate constant of 7.36 (+0.006) 
min-1, and 6.40 (+0.005) min-1 for as isolated BFR and heme-free M52H BFR, respectively.  The 
amount of iron released could be calculated from the end points of the kinetic profiles.  For pH 7, 
49.5%, and 35.1% amount of iron release was obtained for as isolated BFR and heme-free M52H 
BFR, respectively.  For pH 6, the extents of iron release were 48.7%, and 38.8% for as isolated 
BFR and heme-free M52H BFR, respectively. 
 
Figure 5.15. The influence of heme on iron release in E. coli BFR by utilizing 
dithionite as a reductant/FMN and ferrozine as a chelator.  Time-dependent increases of 
ΔA562nm following the addition of 100 µM dithionite, 75 µM FMN to either heme-free 
(M52H) BFR (blue line) or as isolated wild-type containing 1 heme BFR (red line).   
Both BFRs were loaded with 1200 iron ions (0.05 µM BFR) in MBS, and 1 mM 
Ferrozine.  The release reaction was carried out at 15 °C. (A) pH 7 and (B) pH 6. 
Pathlength 1 cm. 
 
 
Previous studies of iron release from BFR showed that the presence of a chelator influenced the 
rate of the release, i.e. the chelator is not an innocent reporter of iron release, but instead is 
actively involved in the process. To remove the influence of the chelator, a modified iron release 
assay was designed, in which the reductant was added to initiate release, and the chelator added 
at increasing time points.  The instantaneous increase in absorbance measured immediately upon 
addition of the chelator represents the concentration of iron that has been released at that time 
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point. To obtain an indication of the true iron release rate, dithionite 100 µM and 100 µM FMN 
were added to the 5 heme BFR solution that contains ~1200 irons at pH 7, and then the ferrozine 
chelator was added at increasing time points. Figure 5.16 shows the instantaneous observed 
jumps in absorbance at 562 nm (due to the formation of Fe(II)-ferrozine-complex) plotted as a 
function of increasing time between addition of reductant and the addition of chelator. The data 
suggest that Fe(II) was not entirely held within the BFR cavity after the reduction of the core.  
About 50% of iron was available as soon as the reductant was added.  This behaviour is very 
different from that previously reported for wild-type BFR. In combination, the data reported here 
suggest that the in vitro heme loading method significantly affects the iron-release properties of 
the protein.  
 
 
Figure 5.16.  The influence of heme on iron release in the absence of ferrozine, a high 
affinity ferrous chelator. Plot of the instantaneous increase of absorbance after the 
addition of the chelator. Time-dependent increases of ΔA562nm following the addition of 
100 µM dithionite, 100 µM FMN to 5 heme loaded BFR.  BFR 0.05 µM BFR loaded 
with 1200 iron ions in MBS, with addition of 100 µM dithionite, 100 µM FMN, 1 mM 
Ferrozine   pH 7, 0.05 µM BFR 15 °C. Pathlength 1 cm. 
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5.4 Discussion 
5.4.1  The mechanism of exogenous heme-binding to BFR 
Overexpressed recombinant E. coli BFR contains very low amounts of heme, usually as low as 
one per 24mer.  Figure 5.2 shows, and as previously reported (73), addition of exogenous heme 
is not incorporated into the BFR heme-binding site.  Structural studies of BFR showed why this 
is so, the heme-binding site is inaccessible from the outside of the protein (73). Previous attempts 
to gain higher levels of heme involved inducing expression of the bfr gene with low levels of 
IPTG, supplementation of cultures with iron and aminolevulinic acid (the first dedicated 
intermediate of heme synthesis), resulting in five hemes per 24mer (27). In this study, various 
amounts of heme were added to BFR, resulting in 5, 6, 7 and 11 hemes per 24mer.  BFR with 12 
hemes was also achieved, but higher amounts of hemein chloride was needed to fully occupy the 
intersubunit heme-binding site.  Addition of a large excess of heme results in heme-binding to 
non-specific sites, which was difficult to remove. 
The mechanism of this reconstitution method is not fully understood and further investigation is 
needed.  However, there are some clear possibilities. With increasing temperature, the BFR 
24mer may dissociate into smaller assemblies, allowing heme to enter the heme-binding sites. 
Heating the 24mer in a low or insufficient ionic strength solution leads to denaturation of the 
dissociating protein.  However, in the presence of high ionic strength (such as 1 M NaCl) the 
secondary structure is stabilized, and facilitates restoration to its native structure upon cooling. 
Another possibility is that a melting of secondary structure within each subunit occurs, enabling 
heme to enter through a newly formed pore in the protein shell.  For example, the two coils 
between the two subunits above the heme-binding site are close and block heme from entering 
the heme-binding site.   It is possible, that at higher temperatures, these coils located above the 
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heme-binding site break apart and allows heme to enter the heme-binding site (51).  
Further confirmation of specific heme-binding to BFR was provided through studies of the BFR 
variant, heme-free M52H, in which the heme-coordinating residue is substituted with histidine. 
These revealed that heme does not bind to this variant, to any significant degree, as only a very 
low amount of heme was detected, with spectral characteristic similar to those of metmyoglobin.  
Thus, the 739 nm band, which is due to the methionyl residues provided by two separate subunits, 
is only observed in the wild-type protein. Note that this coordination is rare with only one other 
example currently known, in surface protein Shp of Streptococcus pyogene (38).    
5.4.2 The effect of heme on iron core formation  
The data from iron core formation revealed that higher heme contents resulted in faster iron core 
oxidation during the late stages of iron core formation; a possible mechanism for this involves 
the bound heme facilitating electron transfer from Fe(II) in the central cavity to the dinuclear 
iron ferroxidase sites. Evidence for this suggestion came from a study of iron uptake into BFR 
reconstituted with Co-protoporphyrin IX compared to that reconstituted with Fe-heme (51). This 
showed no influence on the Phase 3 kinetics of BFR mineralisation in the protein containing Co-
heme. Thus, Fe-heme bound to BFR most likely contributes to some electron- transfer activities 
as a part of BFR ferroxidase activity (51). An assumption made here was that Co-heme and Fe-
heme bind to BFR similarly; this has been shown to be the case for Co-heme-binding to 
cytochrome c, myoglobin, and haemoglobin (74, 75). 
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5.4.3 The role of Heme in iron release from BFR 
Previous studies suggest that heme groups play a major role in both the kinetics and 
thermodynamics of iron release in a heme-containing BFR (27). BFR samples with 5 hemes had 
significantly greater iron release and rate constant compared to BFR containing 1 heme and no 
heme. In the presence of heme there was a 4-fold increase in the rate constant as compared to 
heme-free M52H BFR.  Recently, the structure of the complex between Pa-BFD-BFR was 
solved, providing structural insight into the mechanism of iron mobilization and the electron path 
through the BFR shell to reduce Fe(III) in the BFR cavity (49).  BFD most likely facilities 
release of iron by catalysing the transfer of electrons into the core via the heme.  The proposed 
schematic shows BFD with a [2Fe-2S] cluster, promoting the release of Fe2+ from BFR by 
mediating electrons from FPR (NADPH-dependent ferredoxin reductase) to BFR, to heme, 
Figure 5.17 (49).   
 
 
 
 
 
Figure 5.17. Proposed requirements for BFR iron release in pseudomonas aeruginosa, FPR 
mediates the flow of electrons from NADPH to the mineral in BFR via the heme and that 
interactions between Bfd and BFR promote the release of iron. 
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The reduction potential of Azotobacter vinelandii BFR heme was reported to be -225 mV and -
475 mV (vs. NHE) in the absence and presence of an iron core, respectively. The iron core has a 
reduction potential of -420 mV, which suggested that the heme group plays an important role in 
the reduction of the iron core (51, 76). The data presented here are not consistent with a 
significant role of heme in iron release and are contradicting to previously published data of iron 
release from E. coli BFR and P.aeruginosa BFR.  Here the data suggest that increase heme 
levels only marginally increases the rate of iron release and actually lowers the extent of iron 
release.  To ensure that these unexpected results were not due to a problem with the assay, a 
comparison of as isolated BFR (containing 1 heme) with M52H BFR (containing no heme) was 
made.  This revealed a positive effect of heme, as previously reported. Thus, one possibility is 
that the method of heme loading described here somehow affects the protein so that iron release 
cannot proceed normally.  
Clearly, the heme-binding site itself is not affected in terms of its spectroscopic properties. 
Another possibility is that during the heat treatment the 24mer becomes loosely assembled and 
does not fully regain its homogeneous 24meric structure upon cooling, such that the iron is not 
properly stored within the protein.  Figure 5.16 suggests that some of the iron may be available 
to the chelator before the addition of reductant.  However, it is not clear why an overall lower 
amount of iron would be released from heme-loaded samples.  Further work will be needed to 
resolve this.  
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Chapter 6: General Discussion  
 
6.1 Mechanistic studies of iron uptake by Pennate Diatom Ferritin  
The aim of this project was to investigate the catalytic mechanism of iron uptake in the recently 
discovered diatom ferritin PmFTN.  This was of particular interest because the mechanism of 
mineralisation is not well understood; also PmFTN is the first eukaryotic ferritin with a site C 
located close to the intra-subunit ferroxidase centre. The investigation of PmFTN focused on 
kinetic studies of the wild-type and variant proteins and on characterizing the mechanism by 
which it reacts with iron.   
The data presented in chapters 3 and 4, show that that PmFTN can store iron and kinetic 
measurments of iron oxidation showed an exceedingly rapid initial oxidtion phase involving the 
binding and oxidation of two Fe(II) ions per subunit.  However, the exact mechanism of iron 
uptake in PmFTN remains unclear and further experiments are needed to define what occurs 
following the initial Fe(II) binding and oxidation at the ferroxidase centre.  Nonetheless, several 
conclusions can be drawn about the mineralisation process based on the data presented here. 
The data presented in chapter 3, suggest a mechanism of iron uptake that is different from those 
previously reported for 24mer ferritins.  The ferroxidase centre oxidation reaction is a second 
order reaction that is dependent on the concentration of Fe(II), indicating that iron binding and 
oxidation are closely linked such that they cannot be easily distinguished. Since oxidation occurs 
immediately after Fe(II) binding to PmFTN, the binding event can be viewed as the slow step of 
the reaction.  
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The data from crystallographic studies carried out by the Murphy laboratory (UBC) 
demonstrated that, in the absence of O2, Fe(II) only binds at site A of the ferroxidase centre (57).  
Occupation of sites B and C occurs only when O2 is present. The stopped-flow data presented 
shows saturation of the rapid phase 2 at a level of two Fe(II) ions per monomer of PmFTN.  
Together these results indicate a likely stepwise binding of the Fe(II) and O2 to ferroxidase sites.  
A possible mechanism is one in which ferrous iron binding to site A is followed by the binding 
of the oxidant. Binding of the second ferrous iron to site B, occurs only when the O2 is bound.  
This mechanism accounts for the observed rate dependence, because once the second Fe(II) 
binds, oxidation can occur immediately. Therefore, Fe(II) binging to site B of the ferroxidase site 
is suggested to be the rate determining step, with binding and oxidation events intimately 
connected.  
Previous studies have shown that the ferroxidase centre reaction of PmFTN consumed dioxgen 
in a ratio of 1.9 ± 0.2 Fe(II):O2 (30). The data presented here showed that only two Fe(II) ions 
are initially bound and oxidised per PmFTN subunit and, if it is assumed that the two Fe(II) ions 
bind at sites A and B of the ferroxidase centre, site C is not occupied during the initial oxidation 
reaction. The data suggest that the three Cys residues of PmFtn do not play an important role in 
Fe(II) oxidation and iron uptake, since similar behaviour was observed for alkylated and non-
alkylated forms of wild-protein and for a site-directed variant lacking all three Cys residues.    
In chapter 4, the role of site C was further examined.  We proposed that in PmFTN Glu44 and 
Glu130 may be involved in gating the passage of iron from site B to site C.  The data suggest 
that variants E44Q (in Cys-free background), E44H (alkylated) and H130A (alkylated) all 
exhibited rapid phase 2 oxidation of Fe(II) at the ferroxidase centre with a rate only slightly 
lower than that of the wild-type protein.  However, each of the variants exhibited behaviour 
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distinct from that of the wild-type protein in that relatively little Fe(II) oxidation occurred below 
a level of 1 Fe(II) per subunit.  This is indicative of a change in Fe(II)-binding properties at the 
ferroxidase centre.  This could be due to a significantly higher Fe(II) binding affinity at one site 
of the ferroxidase centre relative to the other.  Alternatively, it could result from negative 
cooperativity of Fe(II)-binding at the two sites of the ferroxidase centre. In both cases, Fe(II) 
binds to the apo-ferroxidase centre in preference to a centre that already contains an Fe(II) ion 
even when O2 is present.  Because Fe(II) oxidation only occurs when the centre contains two 
Fe(II) ions, significant oxidation only occurs when more than 24 Fe(II) ions are added to the 
protein.  It is likely that the affinity of Fe(II) for site B is affected in the variants, since the 
substitution are close to site B (Figure 6.1). In the case of E130A, the residue actually 
coordinates Fe(II) at site B. However, it is noticeable that the two Glu44 variants exhibit 
cooperativity to a greater extent.  
 
 
 
 
 
Figure 6.1. The substituted residues Glu44 and Glu130, shown in red, exhibit 
coordination at site C iron. Glu130 is also observed coordinating to site B.  Water 
molecules are shown as blue spheres. 
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Each of the of E130A, E44Q, and E44H substitutions affected iron oxidation, but for E130A 
PmFTN there was a very significantly enhanced rate of mineralisation compared to wild-type 
and E44Q and E44H proteins.  
It was recently suggested that a unifying mechanism, in which the Fe(III) product at the 
ferroxidase site remains bound to the ferroxidase site but is rapidly displaced by incoming Fe(II), 
could account for the behaviour of all ferritins (67). This unifying mechanism is not consistent 
with the partially filled ferroxidase centre (site C) observed by crystallography (57), nor kinetic 
studies.  Where immediately following oxidation of Fe(II) at the ferroxidase centre small 
absorbance changes were observed which are consistent with the idea that the di-Fe(III) form of 
the centre is unstable, leading to occupation of site C. The rapid ferroxidase centre-catalysed 
oxidation of ferrous iron in PmFTN was not regenerated upon up to 20 hours incubation 
specifying that at least some iron remains present at the ferroxidase site.  Thus, if Fe(III) is 
displaced, the subsequent iron oxidation is much slower than the initial oxidation. The 
mechanism of mineralisation in PmFTN appears to be more complex than either of the two 
general mechanisms previously outlined in which the centre operates either as a gated pore or as 
a stable catalytic centre. In PmFTN there is partial iron migration to the core.  The two distinct 
kinetic phases observed after the second addition of 48 Fe(II) iron may also be associated with 
slow iron migration to the core, likely involving the third iron binding site (site C).  Figure 6.2 
shows a possible mechanistic scheme for PmFTN mineralisation.  The data on E130A are 
particularly interesting because mineralisation occurs much more rapidly than in the wild-type 
protein.  This suggests that the PmFTN ferroxidase centre may have evolved to be less than 
optimally active in terms of mineralisation.  It is likely that site C is important for this and further 
studies of more site directed variants will be needed to investigate this. Initially, this could 
involve the E44A alone and also in combination with the E130A variant. 
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An unknown species that absorbs at 650 nm is observed to form in PmFTN.  Although the 
wavelength maximum absorbance corresponds to that expected for a 1,2-peroxodiferric 
intermediate found in many diiron enzymes, intensity did not decay and so its characteristics are 
not consistent with those observed for such intermediates in other ferritins.  Further experiments 
with PmFTN would help assign the identity of the species observed in the current work and 
would provide insight into the mechanism of iron oxidation at the ferroxidase site. 
 
Figure 6.2. Schematic model of the representation of mineralisation in PmFTN.   Fe2+ 
ions bind at the ferroxidase centre and site C (labelled C) and become oxidised, in the 
presence of oxygen, generating an unstable di-Fe3+ form at the ferroxidase centre. Fe3+ 
ions at site C and the ferroxidase centre are transferred to the internal cavity where they 
nucleate, or become incorporated into, the mineral iron core. Further Fe(III) remains 
iron-bound. Oxidised could occur with significantly altered kinetics.  
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6.2 Mechanistic study of iron release from Bacterioferritin  
Previous mechanistic studies of BFR have shown that heme plays a role in iron release (27).  
That study was carried out with samples of BFR containing zero, one or five hemes per BFR. 
Recently, a novel method for fully loading BFR with heme after purification was devised. It was 
proposed to use this method to more fully investigate the function of heme in iron release.  First, 
it was necessary to establish that the added heme binds at the native heme-binding site and to 
then generate a range of heme loaded BFR samples.    
The data presented in chapters 5 show that various amounts of heme were successfully added to 
BFR, up to 11 hemes per 24mer. Further confirmation of specific heme-binding to BFR was 
provided through studies of the BFR variant, heme-free M52H, in which the heme-coordinating 
Met residue is substituted with His. The data from iron core formation showed BFR samples 
containing higher heme (6 and 11 hemes) resulted in faster iron core formation.  In the latter 
stages of mineralisation, as previously reported (51). Thus, heme accelerates the late phases of 
iron core formation.  
The data suggest that increased heme levels only marginally increases the rate of iron release and 
actually lowers the extent of iron release. Clearly, the heme-binding site itself is not affected in 
terms of its spectroscopic properties. Further investigation is needed; for example, it is possible 
that during the heat treatment the 24mer becomes loosely assembled and does not fully regain its 
homogeneous 24meric structure upon cooling, such that the iron is not properly stored within the 
protein.  Some data suggested that some of the iron may be available to the chelator before the 
addition of reductant.  However, it is not clear why an overall lower amount of iron would be 
released from heme-loaded samples.  Further work will be needed to resolve this.  
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